During	O
postnatal	O
development	O
endogenous	O
neurosteroids	O
influence	O
GABA	O
-	O
ergic	O
neurotransmission	O
of	O
mouse	B-OG
cortical	O
neurons	O

Current	O
address	O
:	O
Pfizer	O
NPRU	O
,	O
The	O
Portway	O
,	O
Granta	O
Park	O
,	O
Cambridge	O
,	O
UK	O
.	O

Joint	O
First	O
Authors	O
.	O

As	O
neuronal	O
development	O
progresses	O
,	O
GABAergic	O
synaptic	O
transmission	O
undergoes	O
a	O
defined	O
program	O
of	O
reconfiguration	O
.	O

For	O
example	O
,	O
GABAA	B-GP
receptor	I-GP
(	O
GABAAR	B-GP
)-	O
mediated	O
synaptic	O
currents	O
,	O
(	O
miniature	O
inhibitory	O
postsynaptic	O
currents	O
;	O
mIPSCs	O
),	O
which	O
initially	O
exhibit	O
a	O
relatively	O
slow	O
decay	O
phase	O
,	O
become	O
progressively	O
reduced	O
in	O
duration	O
,	O
thereby	O
supporting	O
the	O
temporal	O
resolution	O
required	O
for	O
mature	O
network	O
activity	O
.	O

Here	O
we	O
report	O
that	O
during	O
postnatal	O
development	O
of	O
cortical	O
layer	O
2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
GABAAR	B-GP
-	O
mediated	O
phasic	O
inhibition	O
is	O
influenced	O
by	O
a	O
resident	O
neurosteroid	O
tone	O
,	O
which	O
wanes	O
in	O
the	O
second	O
postnatal	O
week	O
,	O
resulting	O
in	O
the	O
brief	O
phasic	O
events	O
characteristic	O
of	O
mature	O
neuronal	O
signalling	O
.	O

Treatment	O
of	O
cortical	O
slices	O
with	O
the	O
immediate	O
precursor	O
of	O
5α	O
-	O
pregnan	O
-	O
3α	O
-	O
ol	O
-	O
20	O
-	O
one	O
(	O
5α3α	O
),	O
the	O
GABAAR	B-GP
-	O
inactive	O
5α	O
-	O
dihydroprogesterone	O
,	O
(	O
5α	O
-	O
DHP	O
),	O
greatly	O
prolonged	O
the	O
mIPSCs	O
of	O
P20	O
pyramidal	O
neurons	O
,	O
demonstrating	O
these	O
more	O
mature	O
neurons	O
retain	O
the	O
capacity	O
to	O
synthesize	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
,	O
but	O
now	O
lack	O
the	O
endogenous	O
steroid	O
substrate	O
.	O

Previously	O
,	O
such	O
developmental	O
plasticity	O
of	O
phasic	O
inhibition	O
was	O
ascribed	O
to	O
the	O
expression	O
of	O
synaptic	O
GABAARs	B-GP
incorporating	O
the	O
α1	O
subunit	O
.	O

However	O
,	O
the	O
duration	O
of	O
mIPSCs	O
recorded	O
from	O
L2	O
/	O
3	O
cortical	O
neurons	O
derived	O
from	O
α1	O
subunit	O
deleted	O
mice	B-OG
,	O
were	O
similarly	O
under	O
the	O
developmental	O
influence	O
of	O
a	O
neurosteroid	O
tone	O
.	O

In	O
addition	O
to	O
principal	O
cells	O
,	O
synaptic	O
GABAARs	B-GP
of	O
L2	O
/	O
3	O
interneurons	O
were	O
modulated	O
by	O
native	O
neurosteroids	O
in	O
a	O
development	O
-	O
dependent	O
manner	O
.	O

In	O
summary	O
,	O
local	O
neurosteroids	O
influence	O
synaptic	O
transmission	O
during	O
a	O
crucial	O
period	O
of	O
cortical	O
neurodevelopment	O
,	O
findings	O
which	O
may	O
be	O
of	O
importance	O
for	O
establishing	O
normal	O
network	O
connectivity	O
.	O

Highlights	O

•	O
Upon	O
postnatal	O
maturation	O
GABAA	B-GP
receptor	I-GP
synaptic	O
inhibition	O
is	O
reduced	O
in	O
duration	O
.•	O
Reduced	O
synthesis	O
of	O
local	O
neurosteroids	O
contributes	O
to	O
this	O
cortical	O
plasticity	O
.•	O
The	O
study	O
reveals	O
a	O
potent	O
mechanism	O
to	O
locally	O
regulate	O
cortical	O
neuron	O
activity	O
.	O

Abbreviations	O

GABAAR	B-GP
α1	I-GP
subunit	O
“	O
knockout	O
”.	O

5α	O
-	O
pregnan	O
-	O
3α	O
-	O
ol	O
-	O
20	O
-	O
one	O
;	O
allopregnanolone	O
.	O

5α	O
-	O
dihydroprogesterone	O
,	O
or	O
5α	O
-	O
pregnane	O
-	O
3	O
,	O
20	O
-	O
dione	O
.	O

5α	B-GP
-	I-GP
reductase	I-GP
.	O

cyclodextrin	O

weighted	O
decay	O
time	O
constant	O
of	O
mIPSC	O
decay	O
.	O

artificial	O
cerebrospinal	O
fluid	O
.	O

analysis	O
of	O
variance	O
statistical	O
test	O
.	O

dimethylsulphoxide	O
.	O

extracellular	O
solution	O
.	O

γ	O
-	O
aminobutyric	O
acid	O
.	O

γ	O
-	O
aminobutyric	O
acid	O
type	O
A	O
receptor	O
.	O

glutamic	B-GP
acid	I-GP
decarboxylase	I-GP
-	O
green	B-GP
fluorescent	I-GP
protein	I-GP
.	O

intracellular	O
solution	O
.	O

Kolmogorov	O
–	O
Smirnov	O
statistical	O
test	O
.	O

cortical	O
layer	O
2	O
/	O
3	O
.	O

miniature	O
inhibitory	O
postsynaptic	O
current	O
.	O

postnatal	O
day	O
.	O

standard	O
error	O
of	O
the	O
mean	O
.	O

time	O
taken	O
for	O
mIPSCs	O
to	O
decay	O
from	O
peak	O
amplitude	O
by	O
50	O
%.	O

tetrodotoxin	O
.	O

ventrobasal	O
.	O

Introduction	O

The	O
postnatal	O
brain	O
undergoes	O
considerable	O
neuronal	O
plasticity	O
to	O
meet	O
the	O
changing	O
demands	O
of	O
rapidly	O
developing	O
networks	O
.	O

During	O
this	O
critical	O
time	O
the	O
duration	O
of	O
synaptic	O
events	O
mediated	O
by	O
GABAARs	B-GP
becomes	O
progressively	O
reduced	O
,	O
permitting	O
postsynaptic	O
neurons	O
to	O
respond	O
to	O
input	O
from	O
certain	O
fast	O
-	O
spiking	O
GABA	O
-	O
ergic	O
interneurons	O
and	O
thereby	O
appropriately	O
influence	O
the	O
temporal	O
window	O
for	O
postsynaptic	O
excitation	O
(	O
Whittington	O
et	O
al	O
.,	O
2011	O
,	O
Deidda	O
et	O
al	O
.,	O
2014	O
,	O
Fritschy	O
and	O
Panzanelli	O
,	O
2014	O
).	O

Alterations	O
to	O
the	O
subunit	O
composition	O
of	O
synaptic	O
GABAARs	B-GP
are	O
implicated	O
in	O
producing	O
these	O
crucial	O
changes	O
to	O
inhibitory	O
postsynaptic	O
current	O
(	O
IPSC	O
)	O
kinetics	O
(	O
Brickley	O
et	O
al	O
.,	O
1996	O
,	O
Okada	O
et	O
al	O
.,	O
2000	O
,	O
Vicini	O
et	O
al	O
.,	O
2001	O
,	O
Juttner	O
et	O
al	O
.,	O
2001	O
,	O
Goldstein	O
et	O
al	O
.,	O
2002	O
,	O
Bosman	O
et	O
al	O
.,	O
2005	O
;	O
Takahashi	O
,	O
2005	O
,	O
Fritschy	O
and	O
Panzanelli	O
,	O
2014	O
,	O
Deidda	O
et	O
al	O
.,	O
2014	O
).	O

GABAARs	B-GP
are	O
members	O
of	O
the	O
Cys	B-GP
-	I-GP
loop	I-GP
transmitter	I-GP
-	I-GP
gated	I-GP
ion	I-GP
channel	I-GP
family	O
and	O
in	O
common	O
with	O
glycine	O
,	O
nicotinic	O
acetylcholine	O
and	O
5HT3	B-GP
receptors	I-GP
are	O
composed	O
of	O
five	O
subunits	O
(	O
Olsen	O
and	O
Sieghart	O
,	O
2008	O
).	O

In	O
mammals	B-OG
19	O
subunit	O
genes	O
underpin	O
the	O
expression	O
of	O
∼	O
20	O
–	O
30	O
native	O
GABAAR	B-GP
subtypes	O
,	O
which	O
display	O
distinct	O
pharmacological	O
and	O
physiological	O
properties	O
(	O
Olsen	O
and	O
Sieghart	O
,	O
2008	O
).	O

In	O
the	O
CNS	O
,	O
these	O
GABAAR	B-GP
subtypes	O
exhibit	O
a	O
heterogeneous	O
expression	O
pattern	O
,	O
which	O
importantly	O
in	O
many	O
neurons	O
is	O
known	O
to	O
change	O
during	O
neonatal	O
development	O
(	O
Olsen	O
and	O
Sieghart	O
,	O
2008	O
,	O
Fritschy	O
and	O
Panzanelli	O
,	O
2014	O
,	O
Rudolph	O
and	O
Mohler	O
,	O
2014	O
).	O

In	O
particular	O
,	O
an	O
increased	O
expression	O
of	O
receptors	O
incorporating	O
the	O
α1	O
subunit	O
(	O
α1	B-GP
-	I-GP
GABAARs	I-GP
)	O
is	O
implicated	O
in	O
the	O
appearance	O
of	O
short	O
duration	O
IPSCs	O
(	O
Okada	O
et	O
al	O
.,	O
2000	O
,	O
Vicini	O
et	O
al	O
.,	O
2001	O
,	O
Peden	O
et	O
al	O
.,	O
2008	O
,	O
Eyre	O
et	O
al	O
.,	O
2012	O
,	O
Deidda	O
et	O
al	O
.,	O
2014	O
,	O
Fritschy	O
and	O
Panzanelli	O
,	O
2014	O
).	O

However	O
,	O
during	O
development	O
of	O
thalamocortical	O
inhibitory	O
synapses	O
,	O
changes	O
to	O
IPSC	O
kinetics	O
occur	O
prior	O
to	O
the	O
temporal	O
expression	O
of	O
the	O
α1	O
subunit	O
(	O
Peden	O
et	O
al	O
.,	O
2008	O
,	O
Brown	O
et	O
al	O
.,	O
2015	O
),	O
implicating	O
,	O
at	O
least	O
in	O
these	O
neurons	O
,	O
additional	O
factor	O
(	O
s	O
)	O
that	O
influence	O
GABAAR	B-GP
ion	B-GP
channel	I-GP
gating	O
properties	O
.	O

Certain	O
naturally	O
occurring	O
neurosteroids	O
act	O
in	O
a	O
non	O
-	O
genomic	O
manner	O
as	O
endogenous	O
positive	O
allosteric	O
modulators	O
of	O
the	O
GABAAR	B-GP
(	O
Belelli	O
and	O
Lambert	O
,	O
2005	O
,	O
Zorumski	O
et	O
al	O
.,	O
2013	O
).	O

The	O
cortical	O
levels	O
of	O
these	O
neurosteroids	O
change	O
during	O
neonatal	O
development	O
(	O
Grobin	O
and	O
Morrow	O
,	O
2001	O
).	O

Furthermore	O
,	O
the	O
enzymes	O
required	O
to	O
synthesize	O
these	O
GABAAR	B-GP
-	O
active	O
steroids	O
are	O
expressed	O
in	O
certain	O
neurons	O
,	O
suggesting	O
that	O
these	O
local	O
neuromodulators	O
may	O
act	O
as	O
paracrine	O
,	O
or	O
autocrine	O
messengers	O
,	O
to	O
locally	O
influence	O
neuronal	O
inhibition	O
(	O
Agis	O
-	O
Balboa	O
et	O
al	O
.,	O
2006	O
,	O
Do	O
Rego	O
et	O
al	O
.,	O
2009	O
,	O
Castelli	O
et	O
al	O
.,	O
2013	O
,	O
Brown	O
et	O
al	O
.,	O
2015	O
).	O

Here	O
,	O
we	O
demonstrate	O
for	O
mouse	B-OG
cortical	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
and	O
interneurons	O
that	O
during	O
early	O
(	O
P7	O
-	O
15	O
)	O
neonatal	O
development	O
,	O
their	O
synaptic	O
GABAARs	B-GP
are	O
influenced	O
by	O
an	O
endogenous	O
neurosteroid	O
tone	O
,	O
which	O
consequently	O
prolongs	O
the	O
duration	O
of	O
phasic	O
GABAergic	O
neurotransmission	O
.	O

During	O
subsequent	O
development	O
this	O
modulation	O
wanes	O
,	O
such	O
that	O
by	O
P20	O
-	O
24	O
it	O
has	O
dissipated	O
,	O
resulting	O
in	O
brief	O
IPSCs	O
,	O
characteristic	O
of	O
mature	O
inhibitory	O
synapses	O
.	O

However	O
,	O
when	O
provided	O
with	O
5α	O
-	O
dihydroprogesterone	O
(	O
5α	O
-	O
DHP	O
),	O
the	O
5α3α	O
precursor	O
,	O
these	O
more	O
mature	O
neurons	O
retain	O
the	O
capacity	O
to	O
synthesise	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
,	O
suggesting	O
that	O
the	O
developmental	O
changes	O
to	O
GABAergic	O
neurotransmission	O
reflect	O
a	O
timed	O
loss	O
of	O
steroid	O
substrate	O
,	O
acting	O
in	O
concert	O
with	O
the	O
established	O
ontogenetic	O
pattern	O
of	O
α1	O
subunit	O
expression	O
.	O

Importantly	O
,	O
neurosteroid	O
levels	O
are	O
not	O
static	O
,	O
but	O
are	O
perturbed	O
in	O
a	O
variety	O
of	O
physiological	O
and	O
pathophysiological	O
conditions	O
(	O
Belelli	O
and	O
Lambert	O
,	O
2005	O
,	O
Zorumski	O
et	O
al	O
.,	O
2013	O
).	O

Therefore	O
,	O
given	O
the	O
role	O
GABAARs	B-GP
may	O
play	O
in	O
a	O
number	O
of	O
disorders	O
including	O
autism	B-DS
,	O
schizophrenia	B-DS
,	O
Fragile	O
X	O
and	O
Down	B-DS
syndrome	I-DS
(	O
Deidda	O
et	O
al	O
.,	O
2014	O
,	O
Rudolph	O
and	O
Mohler	O
,	O
2014	O
),	O
these	O
findings	O
may	O
not	O
only	O
be	O
important	O
in	O
better	O
understanding	O
how	O
phasic	O
GABAergic	O
neurotransmission	O
changes	O
to	O
accommodate	O
the	O
demands	O
of	O
neuronal	O
network	O
activity	O
during	O
development	O
,	O
but	O
may	O
additionally	O
allow	O
new	O
insights	O
into	O
the	O
pathology	O
of	O
certain	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Materials	O
&	O
methods	O

Breeding	O
of	O
mice	B-OG

All	O
animal	B-OG
studies	O
were	O
approved	O
by	O
the	O
University	O
of	O
Dundee	O
Ethical	O
Review	O
Committee	O
(	O
Home	O
Office	O
Project	O
Licenses	O
60	O
/	O
4005	O
and	O
70	O
/	O
8161	O
,	O
Dr	O
.	O
Belelli	O
),	O
and	O
complied	O
with	O
Schedule	O
1	O
of	O
the	O
UK	O
Government	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
,	O
1986	O
.	O

Transgenic	O
α1	O
subunit	O
‘	O
knockout	O
’	O
(	O
α1	O
−/−)	O
mice	B-OG
were	O
generated	O
on	O
a	O
mixed	O
C57BL6	O
-	O
129SvEv	O
background	O
(	O
Sur	O
et	O
al	O
.	O

2001	O
).	O

Transgenic	O
GAD	B-GP
67	I-GP
-	O
GFP	B-GP
“	O
knock	O
-	O
in	O
”	O
mice	B-OG
were	O
generated	O
on	O
a	O
C57BL	O
/	O
6J	O
background	O
as	O
described	O
previously	O
(	O
Tamamaki	O
et	O
al	O
.	O

2003	O
).	O

Electrophysiological	O
experiments	O
were	O
performed	O
on	O
brain	O
slices	O
prepared	O
from	O
the	O
first	O
2	O
–	O
3	O
generations	O
of	O
α1	O
−/−,	O
GAD67	B-GP
-	O
GFP	B-GP
,	O
or	O
corresponding	O
WT	O
offspring	O
from	O
heterozygous	O
(+/−)	O
breeding	O
pairs	O
housed	O
at	O
the	O
University	O
of	O
Dundee	O
.	O

Preparation	O
of	O
brain	O
slices	O
for	O
electrophysiology	O

Cortical	O
slices	O
were	O
prepared	O
from	O
postnatal	O
day	O
(	O
P	O
)	O
P7	O
-	O
24	O
WT	O
,	O
α1	O
−/−,	O
or	O
GAD	B-GP
67	I-GP
-	O
GFP	B-GP
mice	B-OG
of	O
either	O
sex	O
.	O

Mice	B-OG
were	O
killed	O
by	O
cervical	O
dislocation	O
,	O
the	O
brain	O
dissected	O
and	O
placed	O
in	O
ice	O
-	O
cold	O
oxygenated	O
(	O
95	O
%	O
O2	O
/	O
5	O
%	O
CO2	O
)	O
artificial	O
cerebrospinal	O
fluid	O
(	O
aCSF	O
)	O
containing	O
(	O
in	O
mM	O
):	O
225	O
sucrose	O
,	O
2	O
.	O
95	O
KCl	O
,	O
1	O
.	O
25	O
NaH2PO4	O
,	O
26	O
NaHCO3	O
,	O
0	O
.	O
5	O
CaCl2	O
,	O
10	O
MgSO4	O
,	O
10	O
glucose	O
,	O
(	O
pH	O
7	O
.	O
4	O
;	O
328	O
–	O
330	O
mOsm	O
).	O

The	O
brain	O
was	O
sectioned	O
in	O
the	O
coronal	O
plane	O
using	O
a	O
Vibratome	O
series	O
1000	O
PLUS	O
Sectioning	O
System	O
(	O
Intracell	O
,	O
Royston	O
,	O
Hertfordshire	O
,	O
UK	O
).	O

Slices	O
were	O
cut	O
at	O
300	O
–	O
350	O
μm	O
thickness	O
for	O
mice	B-OG
of	O
P15	O
,	O
or	O
older	O
,	O
and	O
400	O
μm	O
,	O
for	O
younger	O
animals	B-OG
.	O

Slices	O
were	O
immediately	O
transferred	O
on	O
to	O
a	O
nylon	O
mesh	O
platform	O
housed	O
within	O
a	O
chamber	O
containing	O
circulating	O
oxygenated	O
extracellular	O
solution	O
(	O
ECS	O
,	O
in	O
mM	O
:	O
126	O
NaCl	O
,	O
26	O
NaHCO3	O
,	O
2	O
.	O
95	O
KCl	O
,	O
1	O
.	O
25	O
NaH2PO4	O
,	O
2	O
MgCl2	O
,	O
2	O
CaCl2	O
,	O
10	O
glucose	O
[	O
306	O
–	O
309	O
mOsm	O
])	O
and	O
allowed	O
to	O
rest	O
at	O
room	O
temperature	O
for	O
a	O
minimum	O
of	O
1	O
h	O
before	O
electrophysiological	O
recording	O
.	O

Voltage	O
-	O
clamp	O
recording	O

During	O
recording	O
,	O
cortical	O
slices	O
were	O
perfused	O
with	O
ECS	O
maintained	O
at	O
35	O
°	O
C	O
using	O
a	O
gravity	O
based	O
perfusion	O
system	O
set	O
to	O
a	O
flow	O
rate	O
of	O
3	O
–	O
5	O
ml	O
/	O
min	O
and	O
recycled	O
to	O
a	O
50	O
ml	O
oxygenated	O
reservoir	O
using	O
a	O
peristaltic	O
pump	O
(	O
Minipuls	O
3	O
,	O
Gilson	O
,	O
UK	O
).	O

Intracellular	O
solution	O
(	O
ICS	O
)	O
containing	O
(	O
in	O
mM	O
):	O
135	O
CsCl	O
,	O
10	O
HEPES	O
,	O
10	O
EGTA	O
,	O
2	O
MgCl2	O
,	O
1	O
CaCl2	O
,	O
2	O
Mg	O
-	O
ATP	O
and	O
5	O
QX	O
-	O
314	O
(	O
pH	O
7	O
.	O
2	O
–	O
7	O
.	O
3	O
,	O
290	O
–	O
300	O
mOsm	O
)	O
was	O
used	O
for	O
whole	O
-	O
cell	O
recording	O
.	O

Patch	O
pipettes	O
were	O
pulled	O
from	O
thick	O
-	O
walled	O
borosilicate	O
glass	O
(	O
0	O
.	O
95	O
mm	O
I	O
.	O
D	O
.	O

1	O
.	O
55	O
mm	O
E	O
.	O
D	O
.	O

Garner	O
Glass	O
Co	O
.	O

Claremont	O
,	O
CA	O
),	O
using	O
a	O
Narashige	O
PC	O
-	O
10	O
electrode	O
puller	O
(	O
Narashige	O
,	O
Japan	O
).	O

When	O
filled	O
with	O
the	O
above	O
ICS	O
,	O
pipettes	O
with	O
an	O
open	O
tip	O
resistance	O
of	O
2	O
–	O
6	O
MΩ	O
were	O
obtained	O
.	O

Neurons	O
were	O
visually	O
identified	O
for	O
investigation	O
using	O
an	O
upright	O
Olympus	O
BX50WI	O
microscope	O
(	O
Olympus	O
,	O
Southall	O
,	O
UK	O
)	O
equipped	O
with	O
IR	O
-	O
DIC	O
optics	O
.	O

Pyramidal	O
neurons	O
located	O
within	O
cortical	O
L2	O
/	O
3	O
were	O
identified	O
based	O
on	O
their	O
canonical	O
pyramidal	O
morphology	O
.	O

L2	O
/	O
3	O
GABAergic	O
interneurons	O
were	O
identified	O
in	O
cortical	O
slices	O
derived	O
from	O
GAD67	B-GP
-	O
GFP	B-GP
“	O
knock	O
-	O
in	O
”	O
mice	B-OG
using	O
epifluorescence	O
microscopy	O
.	O

Neurons	O
were	O
voltage	O
-	O
clamped	O
at	O
−	O
60	O
mV	O
using	O
an	O
Axopatch	O
1D	O
amplifier	O
(	O
Molecular	O
Devices	O
,	O
CA	O
,	O
USA	O
)	O
and	O
filtered	O
at	O
2	O
kHz	O
.	O

GABAAR	B-GP
-	O
mediated	O
mIPSCs	O
were	O
isolated	O
by	O
supplementing	O
the	O
ECS	O
with	O
kynurenic	O
acid	O
(	O
2	O
mM	O
),	O
tetrodotoxin	O
(	O
TTX	O
,	O
500	O
nM	O
)	O
and	O
strychnine	O
(	O
1	O
μM	O
).	O

Data	O
was	O
acquired	O
and	O
digitised	O
(	O
10	O
kHz	O
)	O
using	O
a	O
NIDAQ	O
mx	O
card	O
(	O
National	O
Instruments	O
,	O
TX	O
,	O
USA	O
)	O
and	O
stored	O
directly	O
to	O
PC	O
using	O
WinEDR	O
software	O
(	O
Strathclyde	O
University	O
,	O
UK	O
).	O

Series	O
resistance	O
compensation	O
was	O
applied	O
up	O
to	O
80	O
%.	O

Recordings	O
were	O
omitted	O
from	O
analysis	O
if	O
the	O
series	O
resistance	O
changed	O
by	O
more	O
than	O
20	O
%	O
during	O
the	O
experiment	O
,	O
or	O
if	O
they	O
exceeded	O
15	O
MΩ	O
.	O

Drugs	O
and	O
reagents	O

For	O
in	O
vitro	O
experiments	O
,	O
finasteride	O
,	O
indomethacin	O
,	O
5α3α	O
and	O
5α	O
-	O
DHP	O
were	O
prepared	O
as	O
concentrated	O
stock	O
solutions	O
(	O
1000x	O
final	O
concentration	O
)	O
in	O
DMSO	O
,	O
whereas	O
bicuculline	O
methobromide	O
and	O
TTX	O
were	O
prepared	O
as	O
concentrated	O
stock	O
solutions	O
in	O
distilled	O
water	O
.	O

Drug	O
stock	O
solutions	O
were	O
diluted	O
to	O
the	O
final	O
required	O
concentration	O
in	O
ECS	O
,	O
whereas	O
kynurenic	O
acid	O
was	O
dissolved	O
directly	O
into	O
the	O
ECS	O
.	O

Similarly	O
,	O
α	O
-	O
CD	O
and	O
γ	O
-	O
CD	O
were	O
dissolved	O
directly	O
into	O
the	O
extracellular	O
and	O
intracellular	O
solution	O
.	O

For	O
acute	O
studies	O
with	O
5α3α	O
(	O
1	O
μM	O
),	O
the	O
steroid	O
was	O
perfused	O
directly	O
in	O
to	O
the	O
recording	O
chamber	O
,	O
with	O
the	O
effect	O
determined	O
on	O
mIPSCs	O
acquired	O
after	O
∼	O
7	O
min	O
of	O
drug	O
contact	O
with	O
the	O
slice	O
preparation	O
.	O

To	O
investigate	O
the	O
impact	O
of	O
prolonged	O
exposure	O
to	O
either	O
5α3α	O
(	O
100	O
nM	O
),	O
or	O
5α	O
-	O
DHP	O
(	O
3	O
μM	O
),	O
the	O
test	O
steroid	O
was	O
pre	O
-	O
incubated	O
with	O
the	O
cortical	O
slice	O
at	O
room	O
temperature	O
for	O
>	O
2	O
h	O
,	O
before	O
the	O
tissue	O
was	O
transferred	O
to	O
the	O
recording	O
chamber	O
,	O
where	O
it	O
was	O
continuously	O
perfused	O
with	O
ECS	O
(	O
see	O
Section	O
2	O
.	O
3	O
above	O
)	O
containing	O
the	O
test	O
steroid	O
.	O

Note	O
for	O
some	O
experiments	O
with	O
5α	O
-	O
DHP	O
(	O
3	O
μM	O
)	O
the	O
cortical	O
slice	O
was	O
co	O
-	O
incubated	O
with	O
indomethacin	O
(	O
100	O
μM	O
).	O

The	O
CD	O
studies	O
employed	O
two	O
protocols	O
:	O
the	O
first	O
involved	O
pre	O
-	O
incubating	O
cortical	O
slices	O
in	O
the	O
holding	O
chamber	O
at	O
room	O
temperature	O
with	O
either	O
α	O
-,	O
or	O
γ	O
-	O
CD	O
(	O
1	O
mM	O
,	O
>	O
1	O
h	O
).	O

Recordings	O
were	O
then	O
made	O
with	O
both	O
ECS	O
and	O
ICS	O
containing	O
the	O
CD	O
(	O
1	O
and	O
0	O
.	O
5	O
mM	O
,	O
respectively	O
).	O

In	O
the	O
second	O
protocol	O
,	O
CD	O
was	O
included	O
only	O
in	O
the	O
recording	O
pipette	O
(	O
0	O
.	O
5	O
mM	O
).	O

When	O
the	O
CD	O
was	O
applied	O
to	O
the	O
intracellular	O
compartment	O
alone	O
,	O
mIPSCs	O
were	O
only	O
included	O
for	O
analysis	O
if	O
they	O
were	O
recorded	O
for	O
at	O
least	O
6	O
min	O
after	O
obtaining	O
whole	O
-	O
cell	O
access	O
.	O

To	O
examine	O
the	O
influence	O
of	O
inhibiting	O
the	O
5α	B-GP
-	I-GP
R	I-GP
enzyme	O
,	O
finasteride	O
(	O
50	O
μM	O
)	O
was	O
pre	O
-	O
incubated	O
with	O
the	O
cortical	O
slice	O
in	O
a	O
holding	O
chamber	O
containing	O
oxygenated	O
ECS	O
(	O
at	O
room	O
temperature	O
)	O
for	O
>	O
than	O
4	O
h	O
prior	O
to	O
recording	O
.	O

Subsequent	O
recordings	O
from	O
such	O
slices	O
were	O
made	O
either	O
with	O
a	O
control	O
intracellular	O
pipette	O
solution	O
,	O
or	O
with	O
the	O
pipette	O
containing	O
γ	O
-	O
CD	O
,	O
to	O
determine	O
the	O
combined	O
influence	O
of	O
intracellular	O
γ	O
-	O
CD	O
and	O
finasteride	O
treatment	O
.	O

Note	O
the	O
final	O
DMSO	O
concentration	O
(	O
0	O
.	O
1	O
%)	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
mIPSC	O
parameters	O
measured	O
.	O

Electrophysiological	O
analysis	O

Digitized	O
data	O
was	O
analysed	O
offline	O
using	O
WinEDR	O
/	O
WinWCP	O
software	O
(	O
Strathclyde	O
University	O
,	O
UK	O
).	O

The	O
mIPSCs	O
were	O
identified	O
by	O
an	O
algorithmic	O
detection	O
protocol	O
.	O

To	O
eliminate	O
distal	O
events	O
,	O
which	O
may	O
be	O
affected	O
by	O
imperfect	O
voltage	O
-	O
clamp	O
,	O
Gaussian	O
distributions	O
of	O
10	O
–	O
90	O
%	O
rise	O
time	O
were	O
generated	O
and	O
mIPSCs	O
falling	O
outside	O
the	O
Gaussian	O
limits	O
were	O
excluded	O
.	O

Individual	O
mIPSCs	O
were	O
visually	O
inspected	O
and	O
spurious	O
events	O
omitted	O
.	O

Typically	O
,	O
for	O
each	O
neuron	O
data	O
from	O
50	O
,	O
or	O
more	O
mIPSCs	O
were	O
analysed	O
with	O
respect	O
to	O
their	O
peak	O
amplitude	O
,	O
10	O
–	O
90	O
%	O
rise	O
time	O
,	O
and	O
time	O
taken	O
to	O
decay	O
from	O
peak	O
by	O
50	O
%	O
(	O
T50	O
).	O

Accepted	O
mIPSCs	O
recorded	O
from	O
a	O
single	O
neuron	O
were	O
averaged	O
and	O
fitted	O
with	O
either	O
a	O
mono	O
-	O
exponential	O
(	O
y	O
(	O
t	O
)	O
=	O
Ae	O
(−	O
t	O
/	O
τ	O
)),	O
or	O
bi	O
-	O
exponential	O
(	O
y	O
(	O
t	O
)	O
=	O
A1e	O
(−	O
t	O
/	O
τ1	O
)	O
+	O
A2e	O
(−	O
t	O
/	O
τ2	O
))	O
decay	O
function	O
,	O
where	O
y	O
(	O
t	O
)	O
is	O
the	O
current	O
amplitude	O
at	O
time	O
t	O
,	O
A	O
is	O
the	O
current	O
amplitude	O
and	O
τ	O
is	O
the	O
decay	O
time	O
constant	O
.	O

To	O
compare	O
goodness	O
of	O
fit	O
between	O
a	O
mono	O
-	O
or	O
bi	O
-	O
exponential	O
decay	O
,	O
an	O
F	O
test	O
was	O
applied	O
to	O
the	O
standard	O
deviation	O
of	O
the	O
residuals	O
.	O

The	O
overwhelming	O
majority	O
of	O
mIPSC	O
decay	O
times	O
analysed	O
were	O
best	O
fit	O
by	O
a	O
bi	O
-	O
exponential	O
function	O
.	O

Subsequently	O
,	O
a	O
mean	O
weighted	O
decay	O
constant	O
(	O
τw	O
)	O
was	O
calculated	O
to	O
accommodate	O
the	O
relative	O
contribution	O
of	O
each	O
decay	O
component	O
whereby	O
:	O
τw	O
=	O
τ1P1	O
+	O
τ2P2	O

Here	O
,	O
τ1	O
and	O
τ2	O
are	O
the	O
decay	O
time	O
constants	O
for	O
the	O
first	O
and	O
second	O
exponential	O
functions	O
,	O
and	O
P1	O
and	O
P2	O
are	O
the	O
proportions	O
of	O
current	O
amplitude	O
described	O
by	O
each	O
component	O
i	O
.	O
e	O
.	O
P1	O
=	O
A1A1	O
+	O
A2P2	O
=	O
A2A1	O
+	O
A2	O

All	O
reported	O
data	O
are	O
expressed	O
as	O
mean	O
values	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
S	O
.	O
E	O
.	O
M	O
.).	O

To	O
determine	O
statistical	O
significance	O
,	O
Student	O
'	O
s	O
t	O
-	O
tests	O
(	O
paired	O
,	O
or	O
unpaired	O
)	O
and	O
ANOVA	O
(	O
one	O
or	O
two	O
-	O
way	O
,	O
followed	O
post	O
-	O
hoc	O
by	O
Tukey	O
'	O
s	O
HSD	O
or	O
independent	O
samples	O
t	O
-	O
test	O
,	O
SigmaStat	O
,	O
Systat	O
Software	O
Inc	O
.	O

San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
were	O
used	O
as	O
appropriate	O
.	O

For	O
comparison	O
of	O
cumulative	O
probability	O
distributions	O
of	O
mIPSC	O
T50	O
values	O
,	O
the	O
Kolmogorov	O
-	O
Smirnoff	O
(	O
KS	O
)	O
test	O
was	O
used	O
(	O
SPSS	O
software	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
).	O

Results	O

The	O
influence	O
of	O
development	O
on	O
phasic	O
currents	O
,	O
mediated	O
by	O
synaptic	O
GABAARs	B-GP
of	O
L2	O
/	O
3	O
cortical	O
pyramidal	O
neurons	O

The	O
properties	O
of	O
mIPSCs	O
(	O
frequency	O
,	O
amplitude	O
and	O
kinetics	O
),	O
recorded	O
from	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
obtained	O
from	O
neonatal	O
/	O
juvenile	O
(	O
P7	O
-	O
15	O
)	O
to	O
adolescent	O
(	O
P20	O
-	O
24	O
)	O
mice	B-OG
,	O
changed	O
with	O
development	O
(	O
Fig	O
.	O
1	O
;	O
Table	O
1	O
).	O

Of	O
particular	O
note	O
,	O
with	O
age	O
the	O
mIPSC	O
frequency	O
increased	O
considerably	O
(	O
e	O
.	O
g	O
.	O
P7	O
-	O
8	O
=	O
1	O
.	O
2	O
±	O
0	O
.	O
2	O
Hz	O
,	O
n	O
=	O
55	O
neurons	O
;	O
P20	O
-	O
24	O
=	O
11	O
.	O
7	O
±	O
1	O
.	O
2	O
Hz	O
,	O
n	O
=	O
25	O
neurons	O
–	O
Fig	O
.	O
1	O
;	O
Table	O
1	O
).	O

Furthermore	O
,	O
the	O
mIPSC	O
decay	O
time	O
,	O
as	O
quantified	O
by	O
determination	O
of	O
the	O
weighted	O
decay	O
time	O
constant	O
(	O
τW	O
),	O
decreased	O
with	O
development	O
.	O

Specifically	O
,	O
P7	O
-	O
8	O
neurons	O
exhibited	O
mIPSCs	O
with	O
a	O
relatively	O
prolonged	O
decay	O
(	O
τW	O
=	O
12	O
.	O
1	O
±	O
0	O
.	O
3	O
ms	O
;	O
n	O
=	O
55	O
),	O
that	O
by	O
P15	O
had	O
become	O
significantly	O
reduced	O
(	O
τW	O
=	O
6	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
;	O
n	O
=	O
14	O
;	O
one	O
way	O
ANOVA	O
;	O
p	O
<	O
0	O
.	O
001	O
vs	O
P7	O
-	O
8	O
,	O
Fig	O
.	O
1C	O
,	O
Table	O
1	O
).	O

With	O
the	O
profile	O
of	O
mIPSC	O
decay	O
kinetics	O
between	O
P7	O
-	O
8	O
and	O
P20	O
-	O
24	O
established	O
,	O
investigations	O
now	O
focused	O
on	O
whether	O
the	O
mIPSCs	O
of	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
are	O
influenced	O
by	O
endogenous	O
neurosteroids	O
.	O

Phasic	O
GABAergic	O
transmission	O
from	O
P7	O
-	O
8	O
cortical	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
is	O
influenced	O
by	O
an	O
endogenous	O
neurosteroid	O
tone	O

To	O
test	O
for	O
endogenous	O
modulation	O
of	O
GABAergic	O
neurotransmission	O
by	O
neurosteroids	O
,	O
we	O
utilized	O
γ	O
-	O
CD	O
,	O
a	O
neurosteroid	O
scavenger	O
(	O
Shu	O
et	O
al	O
.,	O
2007	O
,	O
Brown	O
et	O
al	O
.,	O
2015	O
).	O

For	O
P7	O
-	O
8	O
neurons	O
,	O
the	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
protocol	O
(>	O
1	O
h	O
.	O
see	O
Methods	O
)	O
had	O
no	O
effect	O
on	O
the	O
mIPSC	O
frequency	O
,	O
or	O
amplitude	O
(	O
in	O
both	O
cases	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
),	O
but	O
greatly	O
reduced	O
their	O
duration	O
(	O
τW	O
control	O
=	O
12	O
.	O
1	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
55	O
,	O
vs	O
τW	O
γ	O
-	O
CD	O
=	O
8	O
.	O
5	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
20	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2A	O
,	O
F	O
,	O
G	O
Table	O
1	O
).	O

The	O
structurally	O
related	O
α	O
-	O
CD	O
is	O
ineffective	O
in	O
sequestering	O
pregnane	O
steroids	O
,	O
as	O
the	O
pore	O
diameter	O
of	O
the	O
molecule	O
is	O
smaller	O
(	O
6	O
vs	O
8	O
cyclic	O
sugars	O
)	O
than	O
that	O
of	O
γ	O
-	O
CD	O
(	O
Davis	O
and	O
Brewster	O
,	O
2004	O
,	O
Shu	O
et	O
al	O
.,	O
2004	O
,	O
Shu	O
et	O
al	O
.,	O
2007	O
,	O
Brown	O
et	O
al	O
.,	O
2015	O
).	O

Importantly	O
,	O
the	O
equivalent	O
treatment	O
with	O
α	O
-	O
CD	O
had	O
no	O
effect	O
on	O
the	O
mIPSC	O
τW	O
of	O
P7	O
-	O
8	O
neurons	O
(	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2B	O
,	O
F	O
,	O
G	O
).	O

To	O
confirm	O
that	O
the	O
reduced	O
decay	O
times	O
observed	O
following	O
γ	O
-	O
CD	O
were	O
due	O
to	O
neurosteroid	O
sequestration	O
,	O
we	O
pre	O
-	O
incubated	O
P7	O
-	O
8	O
WT	O
cortical	O
brain	O
slices	O
with	O
the	O
5α	B-GP
-	I-GP
reductase	I-GP
inhibitor	O
finasteride	O
(	O
50	O
μM	O
>	O
4	O
h	O
),	O
which	O
significantly	O
reduced	O
the	O
mIPSC	O
duration	O
(	O
τW	O
control	O
=	O
12	O
.	O
1	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
55	O
;	O
τW	O
finasteride	O
=	O
8	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
7	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2C	O
,	O
F	O
,	O
G	O
,	O
Table	O
1	O
).	O

This	O
effect	O
on	O
the	O
mIPSC	O
duration	O
was	O
indistinguishable	O
from	O
that	O
produced	O
by	O
γ	O
-	O
CD	O
(	O
finasteride	O
τW	O
=	O
8	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
7	O
,	O
γ	O
-	O
CD	O
τW	O
=	O
8	O
.	O
5	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
20	O
;	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2F	O
,	O
G	O
,	O
Table	O
1	O
).	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
an	O
endogenous	O
neurosteroid	O
tone	O
influences	O
synaptic	O
GABAARs	B-GP
at	O
P7	O
–	O
8	O
.	O

Interpretation	O
of	O
the	O
combined	O
effects	O
of	O
finasteride	O
and	O
γ	O
-	O
CD	O
is	O
potentially	O
complicated	O
,	O
as	O
given	O
that	O
finasteride	O
is	O
a	O
steroid	O
,	O
it	O
is	O
conceivable	O
that	O
the	O
extracellular	O
γ	O
-	O
CD	O
may	O
sequester	O
this	O
5α	B-GP
-	I-GP
reductase	I-GP
inhibitor	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
intracellular	O
γ	O
-	O
CD	O
alone	O
is	O
equi	O
-	O
effective	O
in	O
influencing	O
the	O
mIPSCs	O
of	O
developing	O
thalamic	O
neurons	O
(	O
Brown	O
et	O
al	O
.,	O
2015	O
),	O
suggesting	O
a	O
protocol	O
to	O
avoid	O
this	O
complexity	O
.	O

Therefore	O
,	O
we	O
first	O
investigated	O
the	O
effect	O
on	O
cortical	O
mIPSCs	O
of	O
incorporating	O
the	O
membrane	O
-	O
impermeant	O
γ	O
-	O
CD	O
(	O
0	O
.	O
5	O
mM	O
)	O
solely	O
in	O
the	O
recording	O
pipette	O
(	O
ICS	O
γ	O
-	O
CD	O
).	O

This	O
treatment	O
(	O
recordings	O
made	O
>	O
6	O
min	O
after	O
achieving	O
the	O
whole	O
-	O
cell	O
recording	O
configuration	O
)	O
significantly	O
reduced	O
the	O
mIPSC	O
τW	O
(	O
control	O
=	O
12	O
.	O
1	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
55	O
;	O
γ	O
-	O
CD	O
ICS	O
:	O
9	O
.	O
2	O
±	O
0	O
.	O
6	O
ms	O
,	O
n	O
=	O
6	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2D	O
,	O
F	O
,	O
G	O
),	O
an	O
effect	O
indistinguishable	O
from	O
that	O
of	O
γ	O
-	O
CD	O
resulting	O
from	O
the	O
pre	O
-	O
incubation	O
protocol	O
(	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
:	O
8	O
.	O
5	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
20	O
,	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2F	O
,	O
G	O
)	O
and	O
not	O
significantly	O
different	O
from	O
that	O
produced	O
by	O
finasteride	O
(	O
50	O
μM	O
)	O
treatment	O
(	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
τW	O
=	O
8	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
7	O
,	O
Fig	O
.	O
2F	O
,	O
G	O
).	O

Finally	O
,	O
we	O
now	O
determined	O
the	O
combined	O
effect	O
of	O
finasteride	O
and	O
γ	O
-	O
CD	O
treatment	O
.	O

For	O
P7	O
-	O
8	O
neurons	O
,	O
treatment	O
of	O
the	O
slice	O
with	O
finasteride	O
(	O
50	O
μM	O
)	O
for	O
>	O
4	O
h	O
,	O
followed	O
by	O
intracellular	O
γ	O
-	O
CD	O
(	O
0	O
.	O
5	O
mM	O
),	O
resulted	O
in	O
mIPSCs	O
with	O
a	O
significantly	O
reduced	O
duration	O
(	O
τw	O
=	O
7	O
.	O
3	O
±	O
0	O
.	O
2	O
ms	O
;	O
n	O
=	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
),	O
that	O
was	O
not	O
significantly	O
different	O
from	O
that	O
produced	O
solely	O
by	O
finasteride	O
,	O
or	O
by	O
intracellular	O
γ	O
-	O
CD	O
alone	O
(	O
p	O
>	O
0	O
.	O
05	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
2E	O
,	O
F	O
,	O
G	O
).	O

The	O
neurosteroid	O
influence	O
on	O
phasic	O
–	O
GABAergic	O
transmission	O
of	O
cortical	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
changes	O
during	O
development	O

We	O
next	O
assessed	O
whether	O
neurosteroids	O
contribute	O
to	O
the	O
developmental	O
changes	O
in	O
the	O
duration	O
of	O
phasic	O
GABAergic	O
events	O
by	O
determining	O
the	O
effect	O
of	O
γ	O
-	O
CD	O
on	O
the	O
mIPSCs	O
of	O
neurons	O
at	O
different	O
stages	O
of	O
development	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

Treatment	O
with	O
γ	O
-	O
CD	O
reduced	O
the	O
decay	O
time	O
of	O
mIPSCs	O
recorded	O
from	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
neurons	O
,	O
relative	O
to	O
their	O
respective	O
controls	O
(	O
Fig	O
.	O
3	O
,	O
Table	O
1	O
).	O

However	O
,	O
the	O
developmental	O
stage	O
significantly	O
influenced	O
the	O
effect	O
of	O
γ	O
-	O
CD	O
on	O
the	O
mIPSC	O
decay	O
time	O
(	O
Fig	O
.	O
3	O
,	O
age	O
×	O
treatment	O
interaction	O
,	O
F3	O
,	O
157	O
=	O
6	O
.	O
15	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
two	O
-	O
way	O
ANOVA	O
),	O
such	O
that	O
by	O
P20	O
-	O
24	O
,	O
γ	O
-	O
CD	O
had	O
no	O
significant	O
effect	O
(	O
control	O
τw	O
=	O
5	O
.	O
4	O
±	O
0	O
.	O
2	O
ms	O
n	O
=	O
25	O
;	O
γ	O
-	O
CD	O
=	O
5	O
.	O
3	O
±	O
0	O
.	O
6	O
ms	O
;	O
n	O
=	O
8	O
;	O
p	O
>	O
0	O
.	O
05	O
;	O
independent	O
samples	O
t	O
-	O
test	O
,	O
Fig	O
.	O
3	O
).	O

Further	O
implicating	O
a	O
changing	O
neurosteroid	O
impact	O
during	O
development	O
,	O
the	O
effect	O
of	O
finasteride	O
(	O
50	O
μM	O
)	O
was	O
also	O
significantly	O
influenced	O
by	O
post	O
-	O
natal	O
age	O
(	O
Fig	O
.	O
3	O
,	O
age	O
×	O
treatment	O
interaction	O
,	O
F2	O
,	O
127	O
=	O
10	O
.	O
47	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
two	O
-	O
way	O
ANOVA	O
),	O
such	O
that	O
,	O
in	O
contrast	O
to	O
P7	O
–	O
P8	O
recordings	O
,	O
finasteride	O
had	O
no	O
significant	O
effect	O
on	O
the	O
mIPSC	O
duration	O
of	O
P20	O
–	O
P24	O
neurons	O
(	O
control	O
τW	O
=	O
5	O
.	O
4	O
±	O
0	O
.	O
2	O
ms	O
;	O
n	O
=	O
25	O
;	O
finasteride	O
τW	O
=	O
5	O
.	O
3	O
±	O
0	O
.	O
2	O
ms	O
;	O
n	O
=	O
6	O
;	O
p	O
>	O
0	O
.	O
05	O
,	O
post	O
-	O
hoc	O
Tukey	O
HSD	O
,	O
Fig	O
.	O
3	O
).	O

Decreased	O
neurosteroid	O
synthesis	O
contributes	O
to	O
the	O
changes	O
to	O
phasic	O
GABAergic	O
transmission	O
evident	O
in	O
P20	O
-	O
24	O
cortex	O

The	O
loss	O
of	O
neurosteroid	O
influence	O
on	O
phasic	O
inhibition	O
of	O
P20	O
-	O
24	O
pyramidal	O
neurons	O
,	O
inferred	O
by	O
both	O
the	O
finasteride	O
and	O
γ	O
-	O
CD	O
experiments	O
,	O
may	O
be	O
due	O
to	O
the	O
synaptic	O
GABAARs	B-GP
becoming	O
neurosteroid	O
-	O
insensitive	O
(	O
Koksma	O
et	O
al	O
.	O

2003	O
),	O
or	O
alternatively	O
a	O
consequence	O
of	O
a	O
decreased	O
neurosteroid	O
synthesis	O
.	O

The	O
neurosteroid	O
interaction	O
with	O
GABAARs	B-GP
may	O
be	O
influenced	O
by	O
factors	O
such	O
as	O
subunit	O
composition	O
and	O
phosphorylation	O
status	O
(	O
Koksma	O
et	O
al	O
.,	O
2003	O
,	O
Belelli	O
and	O
Lambert	O
,	O
2005	O
).	O

We	O
therefore	O
investigated	O
whether	O
GABAARs	B-GP
expressed	O
by	O
P20	O
-	O
24	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
retained	O
neurosteroid	O
sensitivity	O
.	O

The	O
acute	O
bath	O
application	O
of	O
exogenous	O
5α3α	O
(	O
1	O
μM	O
,	O
whereby	O
mIPSCs	O
were	O
analysed	O
before	O
,	O
and	O
after	O
∼	O
7	O
min	O
application	O
of	O
the	O
steroid	O
)	O
resulted	O
in	O
mIPSCs	O
with	O
a	O
significantly	O
prolonged	O
decay	O
phase	O
(	O
control	O
τW	O
:	O
5	O
.	O
5	O
±	O
0	O
.	O
5	O
ms	O
vs	O
1	O
μM	O
5α3α	O
τW	O
:	O
8	O
.	O
7	O
±	O
1	O
.	O
7	O
ms	O
,	O
n	O
=	O
7	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
paired	O
t	O
-	O
test	O
).	O

For	O
isolated	O
single	O
cell	O
studies	O
,	O
acutely	O
applied	O
5α3α	O
acts	O
at	O
nM	O
aqueous	O
concentrations	O
to	O
enhance	O
GABAAR	B-GP
function	O
(	O
Pistis	O
et	O
al	O
.,	O
1997	O
,	O
Belelli	O
and	O
Lambert	O
,	O
2005	O
).	O

Therefore	O
,	O
the	O
relatively	O
limited	O
effect	O
of	O
acutely	O
applied	O
5α3α	O
at	O
the	O
relatively	O
high	O
concentration	O
of	O
1	O
μM	O
might	O
suggest	O
that	O
these	O
cortical	O
synaptic	O
GABAARs	B-GP
are	O
relatively	O
insensitive	O
to	O
the	O
neurosteroid	O
by	O
P20	O
-	O
24	O
.	O

Alternatively	O
,	O
the	O
effect	O
of	O
the	O
steroid	O
when	O
applied	O
acutely	O
to	O
a	O
brain	O
slice	O
may	O
be	O
underestimated	O
.	O

In	O
support	O
of	O
the	O
latter	O
,	O
the	O
general	O
anesthetics	O
etomidate	O
and	O
propofol	O
,	O
which	O
in	O
common	O
with	O
neurosteroids	O
are	O
lipophilic	O
and	O
efficacious	O
GABAAR	B-GP
modulators	O
,	O
require	O
several	O
hours	O
to	O
approach	O
equilibrium	O
within	O
in	O
vitro	O
brain	O
slice	O
preparations	O
(	O
Gredell	O
et	O
al	O
.,	O
2004	O
,	O
Benkwitz	O
et	O
al	O
.,	O
2007	O
).	O

To	O
ascertain	O
whether	O
the	O
GABA	O
modulatory	O
effects	O
of	O
5α3α	O
are	O
underestimated	O
when	O
applied	O
acutely	O
to	O
a	O
cortical	O
slice	O
,	O
we	O
determined	O
the	O
effect	O
of	O
a	O
lower	O
concentration	O
(	O
100	O
nM	O
)	O
of	O
5α3α	O
on	O
the	O
mIPSCs	O
of	O
P20	O
-	O
24	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
but	O
now	O
pre	O
-	O
incubated	O
(>	O
2	O
h	O
),	O
before	O
being	O
continuously	O
applied	O
during	O
the	O
recording	O
.	O

Employing	O
this	O
protocol	O
,	O
the	O
10	O
fold	O
lower	O
concentration	O
of	O
5α3α	O
(	O
100	O
nM	O
)	O
produced	O
a	O
clear	O
and	O
large	O
prolongation	O
of	O
the	O
mIPSC	O
decay	O
(	O
control	O
τW	O
=	O
5	O
.	O
4	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
25	O
vs	O
5α3α	O
100	O
nM	O
τW	O
=	O
12	O
.	O
6	O
±	O
0	O
.	O
9	O
ms	O
,	O
n	O
=	O
5	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
;	O
post	O
-	O
hoc	O
Tukey	O
HSD	O
Fig	O
.	O
4A	O
,	O
C	O
).	O

Importantly	O
,	O
this	O
experiment	O
establishes	O
that	O
P20	O
-	O
24	O
cortical	B-GP
synaptic	I-GP
receptors	I-GP
retain	O
sensitivity	O
to	O
nM	O
aqueous	O
concentrations	O
of	O
this	O
neurosteroid	O
and	O
consequently	O
,	O
the	O
change	O
in	O
mIPSC	O
decay	O
at	O
this	O
stage	O
of	O
development	O
is	O
not	O
due	O
to	O
neurosteroid	O
-	O
insensitive	O
synaptic	O
GABAARs	B-GP
.	O

To	O
determine	O
whether	O
more	O
mature	O
(	O
P20	O
-	O
24	O
)	O
L2	O
/	O
3	O
cortical	O
pyramidal	O
neurons	O
retain	O
the	O
capacity	O
to	O
synthesize	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
the	O
GABAAR	B-GP
-	O
inactive	O
steroid	O
5α	O
-	O
DHP	O
,	O
the	O
immediate	O
precursor	O
of	O
5α3α	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

We	O
had	O
previously	O
shown	O
that	O
a	O
prolonged	O
incubation	O
(>	O
2	O
h	O
),	O
but	O
not	O
a	O
short	O
incubation	O
(	O
30	O
–	O
60	O
min	O
)	O
of	O
thalamic	O
slices	O
with	O
5α	O
-	O
DHP	O
prolonged	O
the	O
mIPSC	O
decay	O
phase	O
of	O
VB	O
neurons	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

Here	O
,	O
pre	O
-	O
incubation	O
of	O
the	O
cortical	O
slice	O
with	O
5α	O
-	O
DHP	O
(	O
3	O
μM	O
)	O
for	O
>	O
2	O
h	O
,	O
followed	O
by	O
continuous	O
perfusion	O
of	O
this	O
steroid	O
during	O
the	O
recording	O
(	O
see	O
Methods	O
),	O
resulted	O
in	O
greatly	O
prolonged	O
mIPSCs	O
(	O
control	O
τW	O
=	O
5	O
.	O
4	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
25	O
vs	O
5α	O
-	O
DHP	O
τW	O
=	O
16	O
.	O
1	O
±	O
0	O
.	O
6	O
ms	O
,	O
n	O
=	O
7	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
-	O
see	O
Fig	O
.	O
4B	O
,	O
C	O
).	O

This	O
effect	O
was	O
markedly	O
reduced	O
by	O
co	O
-	O
incubation	O
with	O
the	O
3α	B-GP
-	I-GP
HSD	I-GP
inhibitor	O
indomethacin	O
(	O
100	O
μM	O
;	O
τW	O
=	O
6	O
.	O
3	O
±	O
0	O
.	O
4	O
ms	O
;	O
n	O
=	O
6	O
;	O
post	O
hoc	O
Tukey	O
HSD	O
p	O
<	O
0	O
.	O
001	O
),	O
or	O
by	O
intracellular	O
(	O
0	O
.	O
5	O
mM	O
)	O
γ	O
-	O
CD	O
(	O
τW	O
=	O
8	O
.	O
7	O
±	O
0	O
.	O
3	O
ms	O
;	O
n	O
=	O
6	O
,	O
post	O
hoc	O
Tukey	O
HSD	O
p	O
<	O
0	O
.	O
001	O
)	O
-	O
Fig	O
.	O
4B	O
,	O
C	O
.	O

Therefore	O
,	O
when	O
provided	O
with	O
the	O
immediate	O
precursor	O
,	O
cortical	O
tissue	O
from	O
P20	O
-	O
24	O
mice	B-OG
retains	O
the	O
ability	O
to	O
synthesize	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
.	O

Furthermore	O
,	O
these	O
data	O
provide	O
additional	O
evidence	O
that	O
their	O
synaptic	O
GABAARs	B-GP
remain	O
neurosteroid	O
sensitive	O
.	O

Phasic	O
GABAergic	O
transmission	O
of	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
is	O
influenced	O
both	O
by	O
an	O
endogenous	O
neurosteroid	O
tone	O
and	O
by	O
the	O
subunit	O
composition	O
of	O
synaptic	O
GABAARs	B-GP

Despite	O
treatment	O
with	O
γ	O
-	O
CD	O
,	O
the	O
mIPSC	O
decay	O
time	O
still	O
decreased	O
with	O
development	O
,	O
with	O
a	O
similar	O
trend	O
observed	O
for	O
finasteride	O
-	O
treated	O
neurons	O
(	O
Fig	O
.	O
3	O
,	O
Table	O
1	O
).	O

These	O
observations	O
suggest	O
that	O
factors	O
additional	O
to	O
neurosteroids	O
influence	O
phasic	O
inhibition	O
during	O
development	O
.	O

Numerous	O
studies	O
have	O
implicated	O
changes	O
to	O
the	O
subunit	O
composition	O
of	O
synaptic	O
GABAARs	B-GP
to	O
be	O
important	O
in	O
this	O
respect	O
,	O
with	O
a	O
particular	O
emphasis	O
on	O
the	O
role	O
of	O
the	O
α1	O
subunit	O
(	O
Rovira	O
and	O
Ben	O
-	O
Ari	O
,	O
1993	O
,	O
Tia	O
et	O
al	O
.,	O
1996	O
,	O
Hollrigel	O
and	O
Soltesz	O
,	O
1997	O
,	O
Dunning	O
et	O
al	O
.,	O
1999	O
,	O
Kapur	O
and	O
Macdonald	O
,	O
1999	O
,	O
Vicini	O
,	O
1999	O
,	O
Vicini	O
et	O
al	O
.,	O
2001	O
,	O
Okada	O
et	O
al	O
.,	O
2000	O
,	O
Ortinski	O
et	O
al	O
.,	O
2004	O
).	O

To	O
investigate	O
whether	O
α1	B-GP
-	I-GP
GABAARs	I-GP
influence	O
mIPSCs	O
during	O
the	O
development	O
(	O
P7	O
–	O
24	O
)	O
of	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
cortical	O
brain	O
slices	O
were	O
prepared	O
from	O
mice	B-OG
engineered	O
to	O
lack	O
the	O
α1	O
subunit	O
(	O
α1	O
−/−).	O

The	O
decay	O
phase	O
of	O
α1	O
−/−	O
mIPSCs	O
was	O
prolonged	O
in	O
comparison	O
to	O
their	O
WT	O
counterparts	O
,	O
but	O
,	O
importantly	O
,	O
this	O
occurred	O
at	O
all	O
ages	O
examined	O
here	O
(	O
two	O
-	O
way	O
ANOVA	O
,	O
age	O
×	O
genotype	O
interaction	O
,	O
F3	O
,	O
139	O
=	O
5	O
.	O
75	O
,	O
p	O
=	O
0	O
.	O
001	O
;	O
for	O
post	O
-	O
hoc	O
WT	O
vs	O
α1	O
−/−	O
comparisons	O
,	O
p	O
<	O
0	O
.	O
001	O
for	O
P7	O
-	O
8	O
,	O
P10	O
,	O
P15	O
and	O
P20	O
,	O
Fig	O
.	O
5	O
).	O

However	O
,	O
in	O
common	O
with	O
WT	O
neurons	O
,	O
the	O
α1	O
−/−	O
mIPSC	O
decay	O
phase	O
became	O
faster	O
with	O
development	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
one	O
way	O
ANOVA	O
,	O
Fig	O
.	O
5	O
;	O
Table	O
2	O
),	O
suggesting	O
that	O
factors	O
other	O
than	O
increased	O
expression	O
of	O
α1	O
-	O
subunit	O
containing	O
GABAARs	B-GP
must	O
contribute	O
to	O
the	O
developmental	O
profile	O
.	O

In	O
agreement	O
,	O
and	O
further	O
implicating	O
a	O
role	O
for	O
neurosteroids	O
,	O
γ	O
-	O
CD	O
treatment	O
significantly	O
reduced	O
the	O
decay	O
time	O
of	O
α1	O
−/−	O
mIPSCs	O
in	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
α1	O
−/−	O
neurons	O
,	O
but	O
in	O
common	O
with	O
their	O
WT	O
counterparts	O
,	O
had	O
no	O
effect	O
on	O
the	O
τw	O
of	O
P20	O
-	O
24	O
α1	O
−/−	O
mIPSCs	O
(	O
two	O
-	O
way	O
ANOVA	O
,	O
age	O
×	O
treatment	O
interaction	O
,	O
F3	O
,	O
58	O
=	O
6	O
.	O
14	O
,	O
p	O
=	O
0	O
.	O
001	O
;	O
for	O
post	O
-	O
hoc	O
control	O
vs	O
γ	O
-	O
CD	O
comparisons	O
,	O
p	O
<	O
0	O
.	O
01	O
for	O
α1	O
−/−	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
neurons	O
and	O
p	O
>	O
0	O
.	O
05	O
for	O
P20	O
-	O
24	O
,	O
Fig	O
.	O
6	O
).	O

Similarly	O
,	O
finasteride	O
(	O
50	O
μM	O
)	O
treatment	O
reduced	O
the	O
τW	O
of	O
P7	O
-	O
8	O
α1	O
−/−	O
mIPSCs	O
,	O
but	O
had	O
no	O
such	O
effect	O
on	O
P20	O
-	O
24	O
α1	O
−/−	O
mIPSCs	O
(	O
two	O
-	O
way	O
ANOVA	O
,	O
age	O
×	O
treatment	O
interaction	O
F2	O
,	O
43	O
=	O
9	O
.	O
87	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
for	O
post	O
-	O
hoc	O
control	O
vs	O
finasteride	O
comparisons	O
,	O
p	O
<	O
0	O
.	O
05	O
for	O
P7	O
–	O
8	O
and	O
p	O
>	O
0	O
.	O
05	O
for	O
P20	O
-	O
24	O
;	O
Fig	O
.	O
6	O
,	O
Table	O
2	O
).	O

These	O
observations	O
suggest	O
that	O
the	O
duration	O
of	O
cortical	O
mIPSCs	O
is	O
influenced	O
throughout	O
the	O
developmental	O
period	O
studied	O
here	O
by	O
the	O
expression	O
of	O
synaptic	B-GP
receptors	I-GP
incorporating	O
the	O
α1	O
subunit	O
,	O
but	O
that	O
changes	O
to	O
the	O
expression	O
of	O
α1	B-GP
-	I-GP
GABAARs	I-GP
are	O
not	O
exclusively	O
responsible	O
for	O
the	O
altered	O
mIPSC	O
kinetics	O
occurring	O
within	O
this	O
developmental	O
window	O
.	O

Furthermore	O
,	O
in	O
common	O
with	O
WT	O
,	O
the	O
waning	O
of	O
a	O
neurosteroid	O
tone	O
is	O
revealed	O
to	O
be	O
an	O
important	O
determinant	O
of	O
the	O
duration	O
of	O
α1	O
−/−	O
mIPSCs	O
.	O

The	O
role	O
of	O
neurosteroids	O
in	O
mediating	O
the	O
developmental	O
changes	O
to	O
phasic	O
GABAergic	O
transmission	O
of	O
L2	O
/	O
3	O
cortical	O
interneurons	O

We	O
next	O
investigated	O
whether	O
the	O
developmentally	O
regulated	O
neurosteroid	O
tone	O
is	O
specific	O
for	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
or	O
is	O
more	O
generally	O
experienced	O
by	O
other	O
neuronal	O
populations	O
.	O

To	O
identify	O
GABA	O
-	O
ergic	O
interneurons	O
we	O
utilized	O
GAD	B-GP
67	I-GP
GFP	B-GP
+	O
mice	B-OG
,	O
engineered	O
to	O
co	O
-	O
express	O
green	B-GP
fluorescent	I-GP
protein	I-GP
(	O
GFP	B-GP
)	O
with	O
the	O
GABA	O
-	O
synthesising	O
67	B-GP
kDa	I-GP
γ	I-GP
-	I-GP
amino	I-GP
decarboxylase	I-GP
(	O
GAD	B-GP
67	I-GP
)	O
enzyme	O
(	O
Tamamaki	O
et	O
al	O
.	O

2003	O
).	O

Co	O
-	O
localization	O
studies	O
revealed	O
that	O
three	O
major	O
interneuron	O
classes	O
present	O
in	O
mouse	B-OG
neocortex	O
,	O
(	O
i	O
.	O
e	O
.	O

calretinin	B-GP
-,	O
parvalbumin	B-GP
-,	O
or	O
somatostatin	B-GP
-	O
expressing	O
)	O
are	O
all	O
GFP	B-GP
-	O
positive	O
(	O
Tamamaki	O
et	O
al	O
.	O

2003	O
).	O

Using	O
epifluorescence	O
microscopy	O
,	O
recordings	O
from	O
P7	O
-	O
8	O
GFP	B-GP
expressing	O
neurons	O
of	O
L2	O
/	O
3	O
,	O
revealed	O
mIPSCs	O
with	O
a	O
decay	O
phase	O
(	O
τW	O
=	O
11	O
.	O
7	O
±	O
0	O
.	O
8	O
ms	O
,	O
n	O
=	O
8	O
;	O
Fig	O
.	O
7	O
A	O
,	O
B	O
,	O
E	O
-	O
see	O
Table	O
3	O
for	O
additional	O
properties	O
),	O
which	O
at	O
this	O
age	O
is	O
similar	O
to	O
that	O
of	O
pyramidal	O
neurons	O
(	O
P7	O
-	O
8	O
L2	O
/	O
3	O
pyramidal	O
τW	O
=	O
12	O
.	O
1	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
55	O
,	O
p	O
>	O
0	O
.	O
05	O
,	O
unpaired	O
t	O
-	O
test	O
),	O
of	O
WT	O
mice	B-OG
.	O

In	O
common	O
with	O
cortical	O
pyramidal	O
neurons	O
,	O
the	O
mIPSC	O
properties	O
of	O
GABA	O
-	O
ergic	O
interneurons	O
changed	O
with	O
development	O
(	O
Table	O
3	O
).	O

In	O
particular	O
,	O
P20	O
-	O
24	O
interneuron	O
mIPSCs	O
exhibited	O
a	O
much	O
reduced	O
decay	O
time	O
(	O
τW	O
=	O
4	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
14	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
,	O
Fig	O
.	O
7	O
C	O
,	O
D	O
,	O
E	O
,	O
Table	O
3	O
),	O
compared	O
to	O
their	O
younger	O
counterparts	O
.	O

For	O
P7	O
-	O
8	O
GABA	O
-	O
ergic	O
interneurons	O
,	O
intracellular	O
γ	O
-	O
CD	O
(	O
0	O
.	O
5	O
mM	O
)	O
had	O
no	O
effect	O
on	O
either	O
the	O
mIPSC	O
peak	O
amplitude	O
,	O
rise	O
time	O
,	O
or	O
frequency	O
(	O
in	O
all	O
cases	O
p	O
>	O
0	O
.	O
05	O
vs	O
control	O
,	O
unpaired	O
t	O
-	O
test	O
),	O
but	O
greatly	O
reduced	O
their	O
decay	O
time	O
(	O
P7	O
-	O
8	O
τW	O
control	O
=	O
11	O
.	O
7	O
±	O
0	O
.	O
8	O
ms	O
,	O
n	O
=	O
8	O
,	O
τW	O
ICS	O
γ	O
-	O
CD	O
=	O
7	O
.	O
6	O
±	O
0	O
.	O
2	O
ms	O
,	O
n	O
=	O
8	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
,	O
Fig	O
.	O
7	O
A	O
,	O
B	O
,	O
E	O
,	O
Table	O
3	O
).	O

However	O
,	O
the	O
effect	O
of	O
intracellular	O
γ	O
-	O
CD	O
was	O
significantly	O
influenced	O
by	O
developmental	O
stage	O
(	O
two	O
-	O
way	O
ANOVA	O
,	O
age	O
×	O
treatment	O
interaction	O
,	O
F1	O
,	O
33	O
=	O
16	O
.	O
23	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
such	O
that	O
the	O
mIPSC	O
decay	O
of	O
P20	O
-	O
24	O
interneurons	O
was	O
no	O
longer	O
influenced	O
by	O
the	O
steroid	O
scavenger	O
(	O
τW	O
control	O
=	O
4	O
.	O
5	O
±	O
0	O
.	O
3	O
ms	O
,	O
n	O
=	O
14	O
;	O
ICS	O
γ	O
-	O
CD	O
τW	O
=	O
4	O
.	O
0	O
±	O
0	O
.	O
4	O
,	O
n	O
=	O
7	O
,	O
p	O
>	O
0	O
.	O
05	O
,	O
unpaired	O
t	O
-	O
test	O
,	O
Fig	O
.	O
7	O
C	O
,	O
D	O
,	O
E	O
,	O
Table	O
3	O
).	O

Therefore	O
,	O
phasic	O
inhibition	O
of	O
L2	O
/	O
3	O
interneurons	O
,	O
in	O
common	O
with	O
pyramidal	O
neurons	O
,	O
changes	O
with	O
development	O
.	O

Furthermore	O
,	O
early	O
in	O
development	O
a	O
neurosteroid	O
tone	O
is	O
experienced	O
by	O
the	O
synaptic	O
GABAARs	B-GP
of	O
both	O
GABA	O
-	O
ergic	O
interneurons	O
and	O
principal	O
neurons	O
,	O
which	O
by	O
P20	O
-	O
24	O
dissipates	O
,	O
resulting	O
in	O
brief	O
phasic	O
inhibitory	O
events	O
.	O

Discussion	O

Endogenous	O
neurosteroids	O
prolong	O
the	O
mIPSCs	O
of	O
cortical	O
L2	O
/	O
3	O
neurons	O
during	O
development	O

Postnatal	O
development	O
is	O
marked	O
by	O
periods	O
of	O
considerable	O
plasticity	O
within	O
cortical	O
circuitry	O
,	O
wherein	O
GABAergic	O
neurotransmission	O
is	O
driven	O
towards	O
rapid	O
and	O
effective	O
phasic	O
inhibition	O
,	O
capable	O
of	O
supporting	O
the	O
complexity	O
of	O
mature	O
cortical	O
processing	O
.	O

During	O
this	O
period	O
,	O
several	O
mechanisms	O
may	O
contribute	O
to	O
the	O
mIPSC	O
decay	O
time	O
,	O
including	O
:	O
alterations	O
in	O
the	O
subunit	O
composition	O
of	O
synaptic	O
GABAARs	B-GP
(	O
Takahashi	O
,	O
2005	O
,	O
Eyre	O
et	O
al	O
.,	O
2012	O
),	O
post	O
-	O
translational	O
modifications	O
of	O
synaptic	O
proteins	O
(	O
Vithlani	O
et	O
al	O
.	O

2011	O
),	O
the	O
extent	O
of	O
receptor	O
clustering	O
(	O
Petrini	O
et	O
al	O
.	O

2003	O
),	O
changes	O
in	O
the	O
kinetics	O
of	O
GABA	O
release	O
and	O
alterations	O
to	O
GABA	O
uptake	O
(	O
Mozrzymas	O
,	O
2004	O
).	O

The	O
latter	O
is	O
influenced	O
by	O
the	O
activity	O
and	O
location	O
of	O
the	O
various	O
GABA	B-GP
transporters	I-GP
.	O

However	O
,	O
whereas	O
the	O
effects	O
of	O
transporter	B-GP
inhibitors	O
on	O
the	O
time	O
course	O
of	O
responses	O
to	O
iontophoretically	O
applied	O
GABA	O
,	O
or	O
on	O
IPSCs	O
evoked	O
by	O
repetitive	O
nerve	O
stimulation	O
are	O
quite	O
evident	O
,	O
they	O
have	O
relatively	O
little	O
effect	O
on	O
the	O
amplitude	O
or	O
kinetics	O
of	O
mIPSCs	O
(	O
Keros	O
and	O
Hablitz	O
,	O
2005	O
,	O
Scimemi	O
,	O
2014	O
).	O

Our	O
results	O
indicate	O
that	O
in	O
addition	O
to	O
a	O
possible	O
involvement	O
of	O
such	O
factors	O
,	O
during	O
postnatal	O
development	O
the	O
mIPSCs	O
of	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
become	O
reduced	O
in	O
duration	O
,	O
at	O
least	O
in	O
part	O
due	O
to	O
a	O
programmed	O
loss	O
of	O
the	O
influence	O
of	O
endogenous	O
neurosteroids	O
upon	O
synaptic	O
GABAARs	B-GP
.	O

The	O
validity	O
of	O
our	O
conclusions	O
is	O
partly	O
dependent	O
on	O
the	O
specificity	O
of	O
γ	O
-	O
CD	O
in	O
sequestering	O
neurosteroids	O
.	O

A	O
previous	O
study	O
reported	O
that	O
β	O
-	O
CD	O
(	O
0	O
.	O
5	O
–	O
1	O
.	O
5	O
mM	O
),	O
when	O
applied	O
to	O
hippocampal	O
neurons	O
prolonged	O
the	O
decay	O
of	O
macroscopic	O
currents	O
mediated	O
by	O
GABAARs	B-GP
(	O
Pytel	O
et	O
al	O
.	O

2006	O
).	O

However	O
,	O
γ	O
-	O
CD	O
treatment	O
of	O
thalamic	O
VB	O
neurons	O
,	O
cortical	O
L2	O
/	O
3	O
interneurons	O
and	O
pyramidal	O
cells	O
induced	O
a	O
marked	O
reduction	O
in	O
the	O
mIPSC	O
decay	O
time	O
early	O
in	O
development	O
,	O
but	O
had	O
no	O
effect	O
on	O
this	O
parameter	O
at	O
later	O
developmental	O
time	O
-	O
points	O
(	O
e	O
.	O
g	O
.	O
P20	O
-	O
24	O
;	O
Brown	O
et	O
al	O
.,	O
2015	O
).	O

Furthermore	O
,	O
pre	O
-	O
incubation	O
with	O
α	O
-	O
CD	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
mIPSC	O
properties	O
at	O
any	O
age	O
studied	O
here	O
and	O
most	O
importantly	O
the	O
effects	O
of	O
γ	O
-	O
CD	O
on	O
P7	O
-	O
8	O
neurons	O
were	O
recapitulated	O
by	O
pre	O
-	O
incubation	O
with	O
the	O
5α	B-GP
−	I-GP
R	I-GP
inhibitor	O
finasteride	O
.	O

A	O
parsimonious	O
explanation	O
for	O
the	O
decreased	O
duration	O
of	O
immature	O
L2	O
/	O
3	O
mIPSCs	O
following	O
γ	O
-	O
CD	O
treatment	O
posits	O
that	O
the	O
steroid	O
-	O
sequestering	O
molecule	O
is	O
effective	O
in	O
forming	O
inclusion	O
complexes	O
with	O
endogenous	O
neurosteroids	O
,	O
whereas	O
the	O
observed	O
insensitivity	O
to	O
α	O
-	O
CD	O
reflects	O
the	O
hydrophobic	O
inner	O
cavity	O
being	O
too	O
small	O
to	O
accommodate	O
steroids	O
(	O
Szejtli	O
,	O
1998	O
,	O
Shu	O
et	O
al	O
.,	O
2004	O
,	O
Brown	O
et	O
al	O
.,	O
2015	O
).	O

Theoretically	O
,	O
the	O
loss	O
of	O
neurosteroid	O
influence	O
on	O
phasic	O
inhibition	O
with	O
development	O
may	O
result	O
from	O
the	O
synaptic	O
GABAARs	B-GP
becoming	O
insensitive	O
to	O
this	O
endogenous	O
modulator	O
(	O
Koksma	O
et	O
al	O
.	O

2003	O
).	O

However	O
,	O
acute	O
application	O
of	O
5α3α	O
(	O
1	O
μM	O
)	O
clearly	O
prolonged	O
mIPSCs	O
recorded	O
from	O
P20	O
-	O
24	O
cortical	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
.	O

Furthermore	O
by	O
pre	O
-	O
incubating	O
the	O
tissue	O
with	O
a	O
lower	O
,	O
aqueous	O
concentration	O
(	O
100	O
nM	O
)	O
of	O
5α3α	O
,	O
we	O
demonstrated	O
these	O
synaptic	O
GABAARs	B-GP
to	O
be	O
highly	O
sensitive	O
to	O
the	O
neurosteroid	O
at	O
this	O
stage	O
of	O
development	O
.	O

Alternatively	O
,	O
a	O
change	O
in	O
steroid	O
enzyme	O
expression	O
,	O
or	O
a	O
lack	O
of	O
steroid	O
substrate	O
(	O
s	O
)	O
may	O
be	O
implicated	O
in	O
this	O
developmental	O
plasticity	O
.	O

We	O
previously	O
demonstrated	O
that	O
incubation	O
of	O
mouse	B-OG
thalamic	O
slices	O
with	O
5α	O
-	O
DHP	O
,	O
the	O
immediate	O
precursor	O
of	O
5α3α	O
,	O
greatly	O
increased	O
the	O
duration	O
of	O
the	O
mIPSCs	O
of	O
VB	O
neurons	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

Similarly	O
here	O
,	O
incubation	O
of	O
P20	O
-	O
24	O
cortical	O
tissue	O
with	O
5α	O
-	O
DHP	O
greatly	O
prolonged	O
the	O
mIPSCs	O
of	O
cortical	O
pyramidal	O
neurons	O
and	O
in	O
common	O
with	O
thalamic	O
neurons	O
,	O
this	O
effect	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
the	O
3α	B-GP
-	I-GP
HSD	I-GP
inhibitor	O
indomethacin	O
,	O
or	O
reversed	O
by	O
intracellular	O
γ	O
-	O
CD	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

Collectively	O
these	O
results	O
suggest	O
that	O
the	O
developmental	O
change	O
to	O
phasic	O
inhibition	O
of	O
cortical	O
pyramidal	O
neurons	O
occurring	O
between	O
P7	O
and	O
P20	O
results	O
in	O
a	O
part	O
from	O
a	O
lack	O
of	O
steroid	O
substrate	O
.	O

Location	O
of	O
neurosteroid	O
synthesis	O
and	O
action	O

Previous	O
histochemical	O
studies	O
support	O
the	O
concept	O
of	O
a	O
local	O
neurosteroid	O
synthesis	O
in	O
cortex	O
.	O

In	O
mouse	B-OG
cortex	O
the	O
staining	O
for	O
mRNA	O
encoding	O
for	O
the	O
5α3α	O
synthesising	O
enzymes	O
5α	B-GP
-	I-GP
reductase	I-GP
Type	I-GP
I	I-GP
(	O
5α	B-GP
-	I-GP
R	I-GP
I	I-GP
)	O
and	O
3α	B-GP
-	I-GP
hydroxysteroid	I-GP
dehydrogenase	I-GP
(	O
3α	B-GP
-	I-GP
HSD	I-GP
),	O
was	O
co	O
-	O
located	O
in	O
layer	O
2	O
/	O
3	O
/	O
5	O
pyramidal	O
neurons	O
(	O
Agis	O
-	O
Balboa	O
et	O
al	O
.	O

2006	O
).	O

The	O
5α	B-GP
-	I-GP
R	I-GP
I	I-GP
staining	O
co	O
-	O
localised	O
with	O
that	O
for	O
the	O
vesicular	B-GP
glutamate	I-GP
transporter	I-GP
(	O
VGLUT1	B-GP
),	O
a	O
marker	O
of	O
glutamatergic	O
neurons	O
(	O
Agis	O
-	O
Balboa	O
et	O
al	O
.	O

2006	O
).	O

By	O
contrast	O
,	O
the	O
5α	B-GP
-	I-GP
R	I-GP
I	I-GP
,	O
or	O
the	O
3α	B-GP
-	I-GP
HSD	I-GP
staining	O
did	O
not	O
co	O
-	O
localize	O
with	O
a	O
marker	O
for	O
GABA	O
-	O
ergic	O
neurons	O
,	O
or	O
for	O
glia	O
(	O
Agis	O
-	O
Balboa	O
et	O
al	O
.	O

2006	O
).	O

In	O
apparent	O
agreement	O
,	O
an	O
antibody	B-GP
raised	O
against	O
5α3α	O
revealed	O
staining	O
for	O
this	O
GABAAR	B-GP
-	O
active	O
steroid	O
in	O
rat	B-OG
cortical	O
L2	O
-	O
6	O
pyramidal	O
neurons	O
,	O
but	O
not	O
in	O
cells	O
that	O
had	O
the	O
appearance	O
of	O
GABA	O
-	O
ergic	O
interneurons	O
,	O
or	O
glia	O
,	O
but	O
note	O
were	O
not	O
categorically	O
identified	O
by	O
specific	O
neurochemical	O
markers	O
of	O
interneuron	O
subtypes	O
(	O
Saalmann	O
et	O
al	O
.	O

2007	O
).	O

However	O
,	O
a	O
recent	O
study	O
identified	O
expression	O
of	O
5αR	B-GP
Type	I-GP
II	I-GP
in	O
cortical	O
GABAergic	O
cells	O
,	O
suggesting	O
that	O
neurosteroid	O
synthesis	O
and	O
action	O
may	O
not	O
always	O
be	O
confined	O
to	O
principal	O
excitatory	O
neurons	O
(	O
Castelli	O
et	O
al	O
.	O

2013	O
).	O

Whether	O
cortical	O
principal	O
cells	O
or	O
interneuron	O
populations	O
are	O
the	O
locus	O
of	O
neurosteroid	O
synthesis	O
is	O
not	O
directly	O
addressed	O
by	O
our	O
finasteride	O
,	O
or	O
intracellular	O
γ	O
-	O
CD	O
experiments	O
.	O

If	O
at	O
P7	O
-	O
8	O
the	O
mode	O
of	O
neurosteroid	O
action	O
is	O
exclusively	O
autocrine	O
,	O
then	O
a	O
ubiquitous	O
expression	O
of	O
steroid	O
-	O
synthesizing	O
enzymes	O
across	O
different	O
neuronal	O
populations	O
would	O
be	O
required	O
.	O

Alternatively	O
,	O
the	O
local	O
steroid	O
concentration	O
present	O
during	O
neonatal	O
development	O
may	O
be	O
sufficient	O
to	O
impact	O
upon	O
GABA	O
-	O
ergic	O
and	O
/	O
or	O
principal	O
neurons	O
,	O
which	O
are	O
incapable	O
of	O
neurosteroid	O
synthesis	O
,	O
thereby	O
inferring	O
a	O
paracrine	O
mode	O
of	O
action	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
required	O
to	O
clarify	O
the	O
relative	O
contribution	O
of	O
autocrine	O
and	O
paracrine	O
neurosteroids	O
to	O
the	O
inhibitory	O
plasticity	O
of	O
the	O
developing	O
cortex	O
.	O

Irrespective	O
of	O
the	O
locus	O
of	O
synthesis	O
,	O
the	O
lipophilic	O
steroid	O
is	O
considered	O
to	O
access	O
the	O
synaptic	O
GABAARs	B-GP
by	O
lateral	O
diffusion	O
via	O
the	O
plasma	O
membrane	O
,	O
a	O
mechanism	O
congruent	O
with	O
the	O
proposed	O
transmembrane	O
neurosteroid	O
binding	O
site	O
on	O
the	O
receptor	O
(	O
Hosie	O
et	O
al	O
.,	O
2006	O
,	O
Chisari	O
et	O
al	O
.,	O
2010	O
).	O

Numerous	O
in	O
vitro	O
electrophysiological	O
studies	O
report	O
enhancement	O
of	O
GABAAR	B-GP
function	O
by	O
low	O
nM	O
aqueous	O
concentrations	O
of	O
5α3α	O
(	O
see	O
Belelli	O
and	O
Lambert	O
,	O
2005	O
),	O
advocating	O
the	O
presence	O
of	O
a	O
relatively	O
high	O
affinity	O
binding	O
site	O
on	O
the	O
GABAAR	B-GP
.	O

However	O
,	O
such	O
neurosteroids	O
are	O
highly	O
lipophilic	O
,	O
permitting	O
much	O
greater	O
local	O
concentrations	O
to	O
accumulate	O
in	O
the	O
vicinity	O
of	O
the	O
receptor	O
,	O
obviating	O
the	O
requirement	O
for	O
a	O
high	O
affinity	O
binding	O
site	O
.	O

Indeed	O
,	O
the	O
proposed	O
low	O
affinity	O
binding	O
site	O
(	O
Chisari	O
et	O
al	O
.	O

2010	O
)	O
is	O
consistent	O
with	O
our	O
observation	O
that	O
even	O
when	O
γ	O
-	O
CD	O
was	O
applied	O
exclusively	O
to	O
the	O
cytosolic	O
compartment	O
,	O
it	O
efficiently	O
removed	O
the	O
neurosteroid	O
influence	O
on	O
synaptic	O
GABAARs	B-GP
of	O
immature	O
cortical	O
pyramidal	O
neurons	O
.	O

The	O
role	O
of	O
GABAAR	B-GP
subunit	O
composition	O
in	O
developmental	O
plasticity	O
of	O
phasic	O
GABAergic	O
neurotransmission	O

The	O
α1	O
subunit	O
mRNA	O
and	O
protein	O
is	O
present	O
in	O
the	O
cortex	O
early	O
in	O
development	O
,	O
albeit	O
at	O
low	O
levels	O
,	O
whereas	O
the	O
converse	O
is	O
true	O
for	O
α2	O
/	O
3	O
subunits	O
,	O
which	O
are	O
highly	O
expressed	O
early	O
in	O
life	O
,	O
before	O
they	O
decrease	O
to	O
lower	O
levels	O
in	O
the	O
mature	O
cortex	O
(	O
Laurie	O
et	O
al	O
.,	O
1992	O
,	O
Fritschy	O
et	O
al	O
.,	O
1994	O
,	O
Pirker	O
et	O
al	O
.,	O
2000	O
).	O

Here	O
the	O
mIPSCs	O
obtained	O
from	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
at	O
P7	O
-	O
8	O
,	O
P10	O
,	O
P15	O
and	O
P20	O
-	O
24	O
exhibited	O
slower	O
decay	O
kinetics	O
c	O
.	O
f	O
.	O
WT	O
controls	O
at	O
each	O
developmental	O
time	O
-	O
point	O
.	O

Since	O
α1	B-GP
-	I-GP
GABAARs	I-GP
are	O
associated	O
with	O
fast	O
decay	O
kinetics	O
(	O
Picton	O
and	O
Fisher	O
,	O
2007	O
),	O
this	O
finding	O
suggests	O
that	O
a	O
proportion	O
of	O
synaptic	O
α1	B-GP
-	I-GP
GABAARs	I-GP
are	O
present	O
even	O
at	O
P7	O
-	O
8	O
in	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
.	O

However	O
,	O
a	O
developmental	O
decrease	O
of	O
the	O
mIPSC	O
decay	O
time	O
of	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
was	O
still	O
evident	O
,	O
implying	O
the	O
presence	O
of	O
additional	O
factors	O
,	O
as	O
previously	O
suggested	O
(	O
Bosman	O
et	O
al	O
.	O

2005	O
).	O

Moreover	O
,	O
the	O
developmental	O
profile	O
of	O
γ	O
-	O
CD	O
sensitivity	O
for	O
mIPSCs	O
from	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
was	O
indistinguishable	O
to	O
WT	O
.	O

In	O
summary	O
,	O
these	O
findings	O
indicate	O
that	O
although	O
the	O
duration	O
of	O
the	O
mIPSCs	O
is	O
influenced	O
by	O
the	O
α1	O
subunit	O
,	O
it	O
is	O
not	O
solely	O
responsible	O
for	O
the	O
developmental	O
changes	O
that	O
occur	O
in	O
the	O
postnatal	O
period	O
P7	O
–	O
20	O
.	O

The	O
results	O
presented	O
here	O
reveal	O
the	O
waning	O
impact	O
during	O
development	O
of	O
the	O
endogenous	O
neurosteroid	O
tone	O
is	O
an	O
additional	O
important	O
factor	O
in	O
influencing	O
phasic	O
GABAergic	O
neurotransmission	O
of	O
both	O
WT	O
and	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
.	O

However	O
,	O
a	O
comparison	O
of	O
the	O
mIPSC	O
decay	O
of	O
P7	O
-	O
8	O
and	O
P20	O
-	O
24	O
α1	O
−/−	O
neurons	O
,	O
when	O
treated	O
with	O
either	O
finasteride	O
,	O
or	O
γ	O
-	O
CD	O
,	O
reveals	O
an	O
additional	O
,	O
as	O
yet	O
unidentified	O
factor	O
(	O
s	O
)	O
that	O
influences	O
phasic	O
GABAergic	O
neurotransmission	O
during	O
postnatal	O
development	O
.	O

The	O
physiological	O
role	O
of	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
during	O
development	O

This	O
study	O
focused	O
on	O
L2	O
/	O
3	O
cortical	O
neurons	O
and	O
found	O
that	O
the	O
synaptic	O
GABAARs	B-GP
expressed	O
on	O
both	O
pyramidal	O
and	O
interneuron	O
populations	O
are	O
developmentally	O
influenced	O
by	O
neurosteroids	O
to	O
modulate	O
the	O
duration	O
of	O
GABAergic	O
synaptic	O
transmission	O
.	O

These	O
changes	O
in	O
neurosteroid	O
influence	O
are	O
occurring	O
during	O
an	O
intense	O
period	O
of	O
synaptogenesis	O
,	O
which	O
may	O
be	O
reflected	O
by	O
our	O
observation	O
that	O
the	O
frequency	O
of	O
mIPSCs	O
increases	O
during	O
postnatal	O
development	O
.	O

Furthermore	O
,	O
at	O
this	O
time	O
GABA	O
may	O
exert	O
a	O
depolarizing	O
effect	O
due	O
to	O
the	O
dominance	O
of	O
the	O
chloride	B-GP
importer	I-GP
NKCC1	B-GP
(	O
Owens	O
et	O
al	O
.,	O
1996	O
,	O
Ben	O
-	O
Ari	O
et	O
al	O
.,	O
2007	O
).	O

Hence	O
,	O
long	O
duration	O
synaptic	O
events	O
may	O
be	O
suited	O
to	O
recruiting	O
voltage	B-GP
-	I-GP
gated	I-GP
calcium	I-GP
channel	I-GP
activation	O
,	O
which	O
in	O
turn	O
may	O
initiate	O
various	O
Ca2	O
+-	O
dependent	O
processes	O
in	O
the	O
neuron	O
.	O

In	O
this	O
scenario	O
,	O
the	O
emergence	O
of	O
mature	O
(	O
hyperpolarizing	O
)	O
GABA	O
-	O
ergic	O
signalling	O
would	O
inversely	O
correlate	O
with	O
the	O
decline	O
of	O
neurosteroid	O
production	O
.	O

Adding	O
complexity	O
,	O
a	O
recent	O
report	O
has	O
demonstrated	O
that	O
neonatal	O
administration	O
of	O
5α3α	O
influences	O
the	O
hippocampal	O
expression	O
of	O
the	O
K	B-GP
+	I-GP
Cl	I-GP
−	I-GP
co	I-GP
-	I-GP
transporter	I-GP
KCC2	B-GP
(	O
Modol	O
et	O
al	O
.,	O
2014	O
).	O

We	O
recently	O
reported	O
a	O
similar	O
developmentally	O
controlled	O
neurosteroid	O
tone	O
in	O
somatosensory	O
thalamocortical	O
neurons	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
).	O

During	O
development	O
,	O
the	O
window	O
of	O
neurosteroid	O
influence	O
on	O
GABA	O
-	O
ergic	O
transmission	O
in	O
the	O
somatosensory	O
thalamus	O
is	O
shorter	O
than	O
that	O
described	O
here	O
for	O
cortex	O
.	O

In	O
thalamic	O
neurons	O
the	O
neurosteroid	O
tone	O
was	O
absent	O
by	O
P10	O
(	O
Brown	O
et	O
al	O
.	O

2015	O
),	O
whereas	O
in	O
cortex	O
this	O
form	O
of	O
endogenous	O
modulation	O
persisted	O
through	O
to	O
P15	O
,	O
but	O
was	O
no	O
longer	O
present	O
by	O
P20	O
-	O
24	O
.	O

The	O
reasons	O
for	O
the	O
distinct	O
temporal	O
regulation	O
between	O
thalamus	O
and	O
cortex	O
are	O
unknown	O
.	O

In	O
addition	O
to	O
thalamus	O
and	O
cortex	O
,	O
previous	O
studies	O
have	O
identified	O
a	O
similar	O
neurosteroid	O
tone	O
in	O
spinal	O
neurons	O
of	O
the	O
dorsal	O
horn	O
(	O
Keller	O
et	O
al	O
.	O

2004	O
),	O
which	O
also	O
exhibits	O
a	O
differential	O
developmental	O
profile	O
for	O
lamina	O
II	O
and	O
lamina	O
III	O
/	O
IV	O
neurons	O
(	O
Inquimbert	O
et	O
al	O
.	O

2008	O
).	O

Hence	O
,	O
the	O
existence	O
of	O
a	O
neurosteroid	O
tone	O
at	O
multiple	O
tiers	O
of	O
the	O
CNS	O
suggests	O
a	O
widespread	O
role	O
during	O
postnatal	O
development	O
.	O

Deciphering	O
the	O
interplay	O
between	O
endogenous	O
neurosteroid	O
synthesis	O
,	O
GABAAR	B-GP
potentiation	O
,	O
and	O
neuronal	O
maturation	O
should	O
therefore	O
be	O
a	O
focus	O
for	O
future	O
studies	O
.	O

The	O
properties	O
of	O
mIPSCs	O
recorded	O
from	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
during	O
postnatal	O
development	O
.	O

A	O
).	O

Traces	O
showing	O
typical	O
current	O
recordings	O
from	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
derived	O
from	O
WT	O
mice	B-OG
at	O
P7	O
(	O
top	O
),	O
P10	O
(	O
middle	O
)	O
and	O
P20	O
(	O
bottom	O
).	O

Note	O
the	O
increase	O
in	O
the	O
frequency	O
of	O
synaptic	O
events	O
with	O
development	O
.	O
B	O
).	O

Averaged	O
,	O
superimposed	O
mIPSCs	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
recorded	O
from	O
representative	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
of	O
P7	O
,	O
P10	O
,	O
P15	O
and	O
P20	O
mice	B-OG
.	O

The	O
decay	O
time	O
decreases	O
progressively	O
with	O
development	O
.	O
C	O
).	O

A	O
graph	O
showing	O
both	O
the	O
net	O
decrease	O
in	O
τW	O
,	O
and	O
the	O
concomitant	O
increase	O
in	O
mIPSC	O
frequency	O
(	O
n	O
=	O
14	O
–	O
55	O
neurons	O
)	O
occurring	O
with	O
development	O
.	O

Symbols	O
represent	O
the	O
mean	O
±	O
S	O
.	O
E	O
.	O
M	O
.	O

GABAergic	O
synaptic	O
currents	O
of	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
are	O
influenced	O
by	O
an	O
endogenous	O
neurosteroid	O
tone	O
during	O
early	O
postnatal	O
development	O
.	O

A	O
-	O
E	O
).	O

Averaged	O
mIPSCs	O
,	O
superimposed	O
and	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
from	O
a	O
representative	O
P7	O
cortical	O
pyramidal	O
neuron	O
during	O
control	O
conditions	O
(	O
black	O
line	O
)	O
and	O
following	O
treatment	O
(	O
grey	O
lines	O
)	O
with	O
either	O
,	O
A	O
)	O
1	O
mM	O
γ	O
-	O
CD	O
,	O
B	O
)	O
1	O
mM	O
α	O
-	O
CD	O
,	O
C	O
)	O
50	O
μM	O
finasteride	O
(	O
Fin	O
),	O
D	O
)	O
0	O
.	O
5	O
mM	O
γ	O
-	O
CD	O
in	O
the	O
ICS	O
only	O
,	O
or	O
E	O
)	O
50	O
μM	O
finasteride	O
+	O
0	O
.	O
5	O
mM	O
γ	O
-	O
CD	O
in	O
the	O
ICS	O
.	O
F	O
).	O

A	O
cumulative	O
probability	O
plot	O
of	O
the	O
mIPSC	O
T50	O
for	O
control	O
P7	O
-	O
8	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
(	O
events	O
pooled	O
from	O
55	O
cells	O
)	O
and	O
P7	O
-	O
8	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
following	O
treatment	O
conditions	O
described	O
above	O
.	O

All	O
treatments	O
apart	O
from	O
α	O
-	O
CD	O
resulted	O
in	O
a	O
significant	O
leftward	O
shift	O
in	O
the	O
T50	O
distribution	O
indicating	O
that	O
these	O
treatments	O
resulted	O
in	O
mIPSCs	O
with	O
reduced	O
decay	O
times	O
compared	O
with	O
control	O
(	O
in	O
all	O
cases	O
p	O
<	O
0	O
.	O
001	O
,	O
KS	O
-	O
test	O
).	O
G	O
)	O
Summary	O
bar	O
graph	O
depicting	O
the	O
mean	O
τw	O
values	O
for	O
P7	O
-	O
8	O
mIPSCs	O
for	O
control	O
and	O
after	O
cyclodextrin	O
/	O
finasteride	O
treatments	O
(	O
n	O
=	O
6	O
–	O
55	O
cells	O
).	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
,	O
***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
.	O
n	O
.	O
s	O
.	O
=	O
not	O
significant	O
,	O
one	O
way	O
ANOVA	O
with	O
Tukey	O
post	O
hoc	O
test	O
.	O

The	O
cortical	O
neurosteroid	O
tone	O
is	O
developmentally	O
regulated	O
.	O

A	O
bar	O
graph	O
showing	O
the	O
effect	O
of	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
(	O
1	O
mM	O
)	O
on	O
the	O
τW	O
of	O
mIPSCs	O
recorded	O
from	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
during	O
development	O
(	O
n	O
=	O
8	O
–	O
55	O
cells	O
).	O

Note	O
that	O
at	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
the	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
τWvs	O
control	O
.	O

For	O
comparison	O
,	O
the	O
effect	O
of	O
finasteride	O
(	O
50	O
μM	O
)	O
preincubation	O
at	O
P7	O
-	O
8	O
and	O
P20	O
-	O
24	O
is	O
also	O
shown	O
(	O
n	O
=	O
6	O
–	O
55	O
cells	O
).	O
†††	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
post	O
hoc	O
Tukey	O
HSD	O
test	O
following	O
two	O
-	O
way	O
ANOVA	O
.	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
,	O
***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
post	O
-	O
hoc	O
independent	O
samples	O
t	O
-	O
test	O
following	O
two	O
-	O
way	O
ANOVA	O
.	O
n	O
.	O
s	O
.	O
=	O
not	O
significant	O
.	O

The	O
independent	O
variables	O
for	O
the	O
two	O
-	O
way	O
ANOVAs	O
were	O
postnatal	O
age	O
and	O
treatment	O
(	O
γ	O
-	O
CD	O
,	O
or	O
finasteride	O
).	O

Illustrated	O
above	O
each	O
developmental	O
time	O
point	O
are	O
the	O
corresponding	O
averaged	O
and	O
superimposed	O
mIPSCs	O
,	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
obtained	O
from	O
representative	O
pyramidal	O
neurons	O
in	O
the	O
absence	O
(	O
control	O
,	O
black	O
line	O
)	O
and	O
following	O
1	O
mM	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
(	O
grey	O
line	O
).	O

The	O
synaptic	O
GABAARs	B-GP
of	O
P20	O
–	O
24	O
L2	O
/	O
3	O
cortical	O
pyramidal	O
neurons	O
are	O
neurosteroid	O
sensitive	O
and	O
furthermore	O
,	O
P20	O
–	O
24	O
cortical	O
brain	O
slices	O
can	O
synthesise	O
GABAAR	B-GP
-	O
active	O
neurosteroids	O
.	O

A	O
).	O

Averaged	O
,	O
superimposed	O
mIPSCs	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
recorded	O
from	O
representative	O
WT	O
L2	O
/	O
3	O
cortical	O
pyramidal	O
neurons	O
from	O
brain	O
slices	O
derived	O
from	O
P20	O
-	O
24	O
mice	B-OG
,	O
under	O
control	O
conditions	O
and	O
following	O
incubation	O
(>	O
120	O
min	O
)	O
with	O
100	O
nM	O
5α3α	O
.	O
B	O
)	O
Averaged	O
,	O
superimposed	O
P20	O
-	O
24	O
mIPSCs	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
recorded	O
under	O
control	O
conditions	O
and	O
following	O
incubation	O
(>	O
120	O
min	O
)	O
with	O
3	O
μM	O
5α	O
-	O
DHP	O
;	O
co	O
-	O
incubation	O
with	O
100	O
μM	O
indomethacin	O
(	O
Indo	O
)	O
and	O
3	O
μM	O
5α	O
-	O
DHP	O
(>	O
120	O
min	O
);	O
or	O
incubation	O
with	O
3	O
μM	O
5α	O
-	O
DHP	O
(>	O
120	O
min	O
)	O
followed	O
by	O
0	O
.	O
5	O
mM	O
ICS	O
γ	O
-	O
CD	O
.	O
C	O
)	O
Summary	O
bar	O
graph	O
illustrating	O
the	O
increase	O
in	O
the	O
mIPSC	O
τw	O
in	O
response	O
to	O
incubation	O
of	O
100	O
nM	O
5α3α	O
;	O
5α	O
-	O
DHP	O
incubation	O
and	O
the	O
much	O
reduced	O
5α	O
-	O
DHP	O
effect	O
following	O
either	O
co	O
-	O
incubation	O
with	O
100	O
μM	O
indomethacin	O
(	O
Indo	O
),	O
or	O
addition	O
of	O
0	O
.	O
5	O
mM	O
γ	O
-	O
CD	O
to	O
the	O
ICS	O
(	O
n	O
=	O
5	O
–	O
25	O
cells	O
).	O
***	O
=	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
,	O
one	O
way	O
ANOVA	O
with	O
Tukey	O
post	O
hoc	O
analysis	O
.	O

The	O
effect	O
of	O
α1	O
subunit	O
deletion	O
on	O
the	O
τWof	O
mIPSCs	O
recorded	O
from	O
L2	O
/	O
3	O
neurons	O
during	O
development	O
.	O

A	O
bar	O
graph	O
comparing	O
τW	O
of	O
mIPSCs	O
recorded	O
from	O
WT	O
and	O
α1	O
−/−	O
L2	O
/	O
3	O
neurons	O
during	O
postnatal	O
development	O
(	O
n	O
=	O
4	O
–	O
13	O
α1	O
−/−	O
neurons	O
).	O

The	O
WT	O
data	O
is	O
adapted	O
from	O
Fig	O
.	O
1	O
.	O

Note	O
that	O
the	O
decay	O
time	O
of	O
mIPSCs	O
of	O
both	O
WT	O
and	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
becomes	O
reduced	O
with	O
age	O
.	O

However	O
,	O
at	O
each	O
developmental	O
stage	O
,	O
mIPSCs	O
recorded	O
from	O
α1	O
−/−	O
neurons	O
exhibit	O
a	O
slower	O
decay	O
c	O
.	O
f	O
.	O
those	O
recorded	O
from	O
equivalent	O
WT	O
neurons	O
(***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
post	O
-	O
hoc	O
independent	O
samples	O
t	O
-	O
test	O
following	O
two	O
-	O
way	O
ANOVA	O
,	O
with	O
postnatal	O
age	O
and	O
genotype	O
as	O
the	O
independent	O
variables	O
).	O

Illustrated	O
above	O
each	O
developmental	O
time	O
point	O
are	O
corresponding	O
averaged	O
and	O
superimposed	O
mIPSCs	O
,	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
obtained	O
from	O
representative	O
WT	O
(	O
black	O
line	O
)	O
and	O
α1	O
−/−	O
pyramidal	O
neurons	O
(	O
grey	O
line	O
).	O

A	O
developmentally	O
-	O
regulated	O
neurosteroid	O
tone	O
influences	O
the	O
decay	O
time	O
of	O
mIPSCs	O
recorded	O
from	O
α1	O
−/−	O
L2	O
/	O
3	O
neurons	O
.	O

A	O
bar	O
graph	O
showing	O
the	O
effect	O
of	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
(	O
1	O
mM	O
)	O
on	O
the	O
τW	O
of	O
mIPSCs	O
recorded	O
from	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
during	O
development	O
(	O
n	O
=	O
4	O
–	O
13	O
cells	O
).	O

In	O
common	O
with	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
,	O
treatment	O
of	O
α1	O
−/−	O
cortical	O
brain	O
slices	O
with	O
γ	O
-	O
CD	O
results	O
in	O
faster	O
decaying	O
mIPSCs	O
at	O
P7	O
-	O
8	O
,	O
P10	O
and	O
P15	O
,	O
but	O
not	O
at	O
P20	O
-	O
24	O
.	O

For	O
comparison	O
,	O
the	O
effect	O
of	O
finasteride	O
(	O
50	O
μM	O
)	O
pre	O
-	O
incubation	O
at	O
P7	O
-	O
8	O
and	O
P20	O
-	O
24	O
is	O
also	O
shown	O
(	O
n	O
=	O
7	O
–	O
14	O
cells	O
).	O
††	O
=	O
p	O
<	O
0	O
.	O
01	O
,	O
†	O
=	O
p	O
<	O
0	O
.	O
05	O
vs	O
control	O
,	O
post	O
hoc	O
Tukey	O
HSD	O
test	O
following	O
a	O
two	O
-	O
way	O
ANOVA	O
.	O
**	O
=	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
post	O
-	O
hoc	O
independent	O
samples	O
t	O
-	O
test	O
following	O
a	O
two	O
-	O
way	O
ANOVA	O
.	O
n	O
.	O
s	O
.	O
=	O
not	O
significant	O
.	O

The	O
independent	O
variables	O
for	O
the	O
two	O
-	O
way	O
ANOVAs	O
were	O
postnatal	O
age	O
and	O
treatment	O
.	O

Illustrated	O
above	O
each	O
developmental	O
time	O
point	O
is	O
the	O
corresponding	O
averaged	O
and	O
superimposed	O
mIPSCs	O
,	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
,	O
obtained	O
from	O
representative	O
pyramidal	O
neurons	O
of	O
WT	O
and	O
α1	O
−/−	O
in	O
the	O
absence	O
(	O
control	O
,	O
black	O
line	O
)	O
and	O
following	O
1	O
mM	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
(	O
grey	O
line	O
).	O

The	O
effect	O
of	O
intracellular	O
γ	O
-	O
cyclodextrin	O
(	O
0	O
.	O
5	O
mM	O
)	O
on	O
the	O
decay	O
kinetics	O
of	O
mIPSCs	O
recorded	O
from	O
P7	O
and	O
P20	O
-	O
24	O
L2	O
/	O
3	O
cortical	O
GAD67	B-GP
-	O
GFP	B-GP
+	O
neurons	O
.	O

A	O
,	O
C	O
).	O

Superimposed	O
,	O
averaged	O
mIPSCs	O
normalised	O
with	O
respect	O
to	O
peak	O
amplitude	O
from	O
representative	O
P7	O
(	O
A	O
)	O
and	O
P20	O
(	O
C	O
)	O
control	O
L2	O
/	O
3	O
GFP	B-GP
+	O
neurons	O
(	O
black	O
line	O
)	O
and	O
L2	O
/	O
3	O
GFP	B-GP
+	O
neurons	O
in	O
which	O
the	O
intracellular	O
solution	O
contained	O
0	O
.	O
5	O
mM	O
γ	O
-	O
CD	O
(	O
grey	O
line	O
)	O
at	O
P7	O
(	O
A	O
)	O
and	O
P20	O
(	O
C	O
).	O
B	O
,	O
D	O
).	O

Cumulative	O
probability	O
plots	O
of	O
the	O
mIPSC	O
T50	O
for	O
P7	O
(	O
B	O
)	O
and	O
P20	O
-	O
24	O
neurons	O
(	O
D	O
)	O
control	O
(	O
black	O
line	O
)	O
and	O
ICS	O
+	O
γ	O
-	O
CD	O
(	O
grey	O
line	O
).	O

In	O
each	O
case	O
events	O
were	O
pooled	O
from	O
n	O
=	O
8	O
GFP	B-GP
+	O
cells	O
(	O
P7	O
control	O
),	O
n	O
=	O
8	O
GFP	B-GP
+	O
cells	O
(	O
P7	O
ICS	O
+	O
γ	O
-	O
CD	O
),	O
n	O
=	O
14	O
GFP	B-GP
+	O
cells	O
(	O
P20	O
-	O
24	O
control	O
),	O
and	O
n	O
=	O
7	O
GFP	B-GP
+	O
cells	O
(	O
P20	O
-	O
24	O
ICS	O
+	O
γ	O
-	O
CD	O
).	O

For	O
P7	O
,	O
but	O
not	O
for	O
P20	O
-	O
24	O
cells	O
,	O
the	O
mIPSC	O
T50	O
distribution	O
is	O
left	O
-	O
shifted	O
indicating	O
that	O
all	O
mIPSCs	O
recorded	O
from	O
P7	O
GFP	B-GP
+	O
cells	O
treated	O
with	O
intracellular	O
γ	O
-	O
CD	O
,	O
exhibited	O
faster	O
decay	O
kinetics	O
,	O
compared	O
with	O
control	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
KS	O
-	O
test	O
).	O
E	O
).	O

A	O
summary	O
bar	O
graph	O
showing	O
a	O
significant	O
decrease	O
in	O
the	O
mIPSC	O
τW	O
following	O
intracellular	O
γ	O
-	O
CD	O
treatment	O
at	O
P7	O
,	O
but	O
not	O
at	O
P20	O
-	O
24	O
.	O
n	O
.	O
s	O
.	O
=	O
not	O
-	O
significant	O
;	O
***	O
=	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
,	O
post	O
-	O
hoc	O
independent	O
samples	O
t	O
-	O
test	O
following	O
two	O
-	O
way	O
ANOVA	O
,	O
with	O
postnatal	O
age	O
and	O
treatment	O
as	O
the	O
independent	O
variables	O
.	O

A	O
summary	O
of	O
the	O
impact	O
of	O
development	O
and	O
γ	O
-	O
CD	O
,	O
or	O
finasteride	O
preincubation	O
on	O
the	O
mIPSC	O
properties	O
of	O
WT	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
.*	O
=	O
p	O
<	O
0	O
.	O
05	O
,***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
unpaired	O
t	O
-	O
test	O
.†††	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
one	O
way	O
ANOVA	O
with	O
Tukey	O
post	O
hoc	O
test	O
.	O

P7	O
/	O
8	O

P10	O

P15	O

P20	O
-	O
24	O

Control	O
(	O
n	O
=	O
55	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
20	O
)	O

FIN	O
(	O
n	O
=	O
7	O
)	O

Control	O
(	O
n	O
=	O
20	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
11	O
)	O

Control	O
(	O
n	O
=	O
14	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
12	O
)	O

Control	O
(	O
n	O
=	O
25	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
8	O
)	O

FIN	O
(	O
n	O
=	O
6	O
)	O

Peak	O
amplitude	O
(	O
pA	O
)	O

−	O
50	O
±	O
3	O

−	O
48	O
±	O
3	O

−	O
63	O
±	O
3	O

−	O
46	O
±	O
2	O

−	O
47	O
±	O
4	O

−	O
54	O
±	O
3	O

−	O
45	O
±	O
1	O
*	O

−	O
42	O
±	O
2	O

−	O
42	O
±	O
3	O

−	O
50	O
±	O
5	O

Rise	O
time	O
(	O
ms	O
)	O

0	O
.	O
6	O
±	O
0	O
.	O
1	O

0	O
.	O
6	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
6	O
±	O
0	O
.	O
1	O

0	O
.	O
6	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

τW	O
(	O
ms	O
)	O

12	O
.	O
1	O
±	O
0	O
.	O
3	O

8	O
.	O
5	O
±	O
0	O
.	O
2	O
†††	O

8	O
.	O
5	O
±	O
0	O
.	O
3	O
†††	O

10	O
.	O
5	O
±	O
0	O
.	O
5	O

7	O
.	O
3	O
±	O
0	O
.	O
4	O
***	O

6	O
.	O
5	O
±	O
0	O
.	O
3	O

5	O
.	O
2	O
±	O
0	O
.	O
3	O
*	O

5	O
.	O
4	O
±	O
0	O
.	O
2	O

5	O
.	O
3	O
±	O
0	O
.	O
6	O

5	O
.	O
3	O
±	O
0	O
.	O
2	O

Frequency	O
(	O
Hz	O
)	O

1	O
.	O
2	O
±	O
0	O
.	O
2	O

1	O
.	O
2	O
±	O
0	O
.	O
2	O

1	O
.	O
8	O
±	O
0	O
.	O
4	O

2	O
.	O
2	O
±	O
0	O
.	O
3	O

2	O
.	O
6	O
±	O
0	O
.	O
5	O

12	O
.	O
9	O
±	O
2	O
.	O
0	O

12	O
.	O
4	O
±	O
2	O
.	O
8	O

11	O
.	O
7	O
±	O
1	O
.	O
2	O

12	O
.	O
6	O
±	O
3	O
.	O
3	O

9	O
.	O
1	O
±	O
0	O
.	O
7	O

A	O
summary	O
of	O
the	O
impact	O
of	O
development	O
and	O
γ	O
-	O
CD	O
pre	O
-	O
incubation	O
on	O
the	O
properties	O
of	O
mIPSCs	O
of	O
α1	O
−/−	O
L2	O
/	O
3	O
pyramidal	O
neurons	O
.**	O
=	O
p	O
<	O
0	O
.	O
01	O
,***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
Student	O
'	O
s	O
unpaired	O
t	O
-	O
test	O
.†	O
=	O
p	O
<	O
0	O
.	O
05	O
,††	O
=	O
p	O
<	O
0	O
.	O
01	O
,	O
vs	O
control	O
,	O
one	O
way	O
ANOVA	O
with	O
Tukey	O
post	O
hoc	O
analysis	O
.	O

P7	O
-	O
8	O

P10	O

P15	O

P20	O
-	O
24	O

Control	O
(	O
n	O
=	O
5	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
8	O
)	O

FIN	O
(	O
n	O
=	O
5	O
)	O

Control	O
(	O
n	O
=	O
4	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
4	O
)	O

Control	O
(	O
n	O
=	O
12	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
9	O
)	O

Control	O
(	O
n	O
=	O
13	O
)	O

γ	O
-	O
CD	O
(	O
n	O
=	O
11	O
)	O

FIN	O
(	O
n	O
=	O
7	O
)	O

Peak	O
amplitude	O
(	O
pA	O
)	O

−	O
57	O
±	O
3	O

−	O
52	O
±	O
2	O

−	O
60	O
±	O
6	O

−	O
49	O
±	O
2	O

−	O
51	O
±	O
6	O

−	O
41	O
±	O
3	O

−	O
39	O
±	O
3	O

−	O
49	O
±	O
3	O

−	O
47	O
±	O
2	O

−	O
57	O
±	O
3	O
.	O
8	O

Rise	O
time	O
(	O
ms	O
)	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
5	O
±	O
0	O
.	O
1	O

0	O
.	O
4	O
±	O
0	O
.	O
1	O

τW	O
(	O
ms	O
)	O

18	O
.	O
7	O
±	O
2	O
.	O
0	O

12	O
.	O
2	O
±	O
1	O
.	O
0	O
††	O

12	O
.	O
9	O
±	O
0	O
.	O
9	O
†	O

16	O
.	O
0	O
±	O
1	O
.	O
3	O

9	O
.	O
2	O
±	O
1	O
.	O
1	O
***	O

13	O
.	O
5	O
±	O
0	O
.	O
9	O

9	O
.	O
8	O
±	O
0	O
.	O
4	O
**	O

7	O
.	O
9	O
±	O
0	O
.	O
4	O

7	O
.	O
9	O
±	O
0	O
.	O
6	O

8	O
.	O
8	O
±	O
0	O
.	O
4	O

Frequency	O
(	O
Hz	O
)	O

ND	O

ND	O

ND	O

0	O
.	O
8	O
±	O
0	O
.	O
3	O

1	O
.	O
5	O
±	O
0	O
.	O
3	O

3	O
.	O
9	O
±	O
0	O
.	O
7	O

3	O
.	O
5	O
±	O
1	O
.	O
0	O

12	O
.	O
5	O
±	O
1	O
.	O
6	O

8	O
.	O
5	O
±	O
1	O
.	O
2	O

ND	O

A	O
summary	O
of	O
the	O
effects	O
of	O
intracellular	O
γ	O
-	O
CD	O
treatment	O
on	O
the	O
properties	O
of	O
mIPSCs	O
of	O
L2	O
/	O
3	O
GAD	O
67	O
GFP	O
+	O
neurons	O
.***	O
=	O
p	O
<	O
0	O
.	O
001	O
,	O
vs	O
control	O
,	O
unpaired	O
t	O
-	O
test	O
.	O

P7	O
control	O
(	O
n	O
=	O
8	O
)	O

P7	O
γ	O
-	O
CD	O
(	O
n	O
=	O
8	O
)	O

P20	O
-	O
24	O
control	O
(	O
n	O
=	O
14	O
)	O

P20	O
-	O
24	O
γ	O
-	O
CD	O
(	O
n	O
=	O
7	O
)	O

Peak	O
amplitude	O
(	O
pA	O
)	O

−	O
74	O
±	O
7	O

−	O
61	O
±	O
5	O

−	O
62	O
±	O
4	O

−	O
59	O
±	O
7	O

Rise	O
time	O
(	O
ms	O
)	O

0	O
.	O
4	O
±	O
0	O
.	O
1	O

0	O
.	O
4	O
±	O
0	O
.	O
1	O

0	O
.	O
4	O
±	O
0	O
.	O
1	O

0	O
.	O
4	O
±	O
0	O
.	O
1	O

τW	O
(	O
ms	O
)	O

11	O
.	O
7	O
±	O
0	O
.	O
8	O

7	O
.	O
6	O
±	O
0	O
.	O
2	O
***	O

4	O
.	O
5	O
±	O
0	O
.	O
3	O

4	O
.	O
0	O
±	O
0	O
.	O
4	O

Frequency	O
(	O
Hz	O
)	O

0	O
.	O
3	O
±	O
0	O
.	O
1	O

0	O
.	O
2	O
±	O
0	O
.	O
1	O

2	O
.	O
7	O
±	O
0	O
.	O
5	O

2	O
.	O
1	O
±	O
0	O
.	O
9	O

